Document:

EX-10.12

 Exhibit 10.12 

EXHIBIT C 
 Contingent
Value Rights Agreement 
 This CONTINGENT VALUE RIGHTS AGREEMENT, dated as of January 23, 2021 (this “Agreement”),
is entered into by and among Palladio Biosciences, Inc., a Delaware corporation ( “Palladio”), Srini Akkaraju, solely in his capacity as the representative of the holders of the CVRs (the “Holder
Representative”), and United Medicines Biopharma Limited, a private company limited by shares incorporated in England (“UM”). 

RECITALS 
 WHEREAS, on
January 23, 2021, Palladio, UM and a subsidiary of UM entered into that certain Agreement and Plan of Reorganization (as amended, the “Merger Agreement”), pursuant to which Palladio became a wholly-owned subsidiary of UM. 

WHEREAS, it was a condition to the Closing for the parties hereto to execute and deliver this Agreement to the other parties hereto. 

WHEREAS, pursuant to the Merger Agreement, the CVRs were to be allocated to the Holders as provided for in the Merger Agreement. 

AGREEMENT 
 The parties to this
Agreement, for and in consideration of the premises and the consummation of the transactions referred to above, intending to be legally bound, hereby mutually covenant and agree, for the equal and proportionate benefit of all Holders, as follows:

 SECTION 1 DEFINITIONS 
 1.1
Definitions. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Merger Agreement. The following terms shall have the meanings ascribed to them below: 

“Approval” or “Approved” means, with respect to the Milestone Product in any regulatory jurisdiction, approval from the
applicable Regulatory Authority sufficient to manufacture, distribute, use (including in clinical trials) and sell the Milestone Product in such regulatory jurisdiction in accordance with laws including receipt of pricing and reimbursement
approvals, where applicable. 
 “Business Day” means a day which is not a Saturday or Sunday or on which banks generally are required to be
closed in New York, New York. 
 “CVR Register” has the meaning set forth in Section 2.3(b). 

“CVR Share Payment” means a number of UM B Ordinary Shares equal to the quotient determined by dividing (i) the Milestone Payment by
(ii) Per Ordinary Share Price. 
 “CVRs” means the rights of Holders to receive a contingent payment pursuant to this Agreement. 

“Divestiture” (and other correlative terms) means any transaction in which the Milestone Product and the corresponding intellectual property
assets related to the same are divested or otherwise transferred by way of merger, consolidation, asset acquisition, sale or other similar transfer, including through the transfer by UM of a majority of the voting equity of Palladio. 

 “Holder” means, at the relevant time, a Person in whose name a CVR is registered in the CVR
Register. 
 “Holder Representative” means the Holder Representative named in the first paragraph of this Agreement, until written notice
of a successor Holder Representative has been provided to UM following its appointment by the Holders. 
 “Major Market Country” means
United States, France, Germany, Italy, Spain, the United Kingdom and Japan. 
 “Milestone Payment” means $39,679,834.70. 

“Milestone Period” means the period starting on the date hereof and ending on the earliest of (i) the date, if any, upon which the
Milestone Payment has been paid by Palladio as required by this Agreement and (ii) the fifth (5th) anniversary of the Closing Date. 

“Milestone Product” means Lixivaptan for the treatment of Polycystic Kidney Disease. 

“Milestone Trigger” means the commencement of the first Phase 3 Clinical Trial in any Major Market Country. 

“Payment Date” means the date of the Milestone Payment’s payment to the Holders pursuant to Section 2.5. 

“Per Ordinary Share Price” means, as of the date of the occurrence of the Milestone Trigger: (i) if the UM B Ordinary Shares are traded
on a securities exchange, then the average of the Volume Weighted Average Price of a UM B Ordinary Share over a five (5) day trading period ending on the date of the occurrence of the Milestone Trigger; (ii) if the UM B Ordinary Shares are
traded over-the-counter, then the average of the closing bid and asked prices of a UM B Ordinary Share quoted on the NASDAQ system (or similar system) over the five
(5) day period ending on the date of the occurrence of the Milestone Trigger; or (iii) if on such date the UM B Ordinary Shares are not listed on any securities exchange or quoted in the NASDAQ National Market or the over-the-counter market, then the price per share of a UM B Ordinary Share as determined in good faith by the Board of Directors of UM or, if requested by the Holder
Representative, the price per share determined by a mutually agreed independent third party appraiser. 
 “Percentage” means, with respect
to a Holder, a percentage equal to (a) the number of CVRs held by such Holder (as indicated on the CVR Register), divided by (b) the total number of CVRs held by all Holders (other than Palladio with respect to the Abandoned CVRs). 

“Permitted Assignment” means a transfer of one or more CVRs: (a) upon death by will or intestacy; (b) by instrument to an inter
vivos or testamentary trust in which the CVRs are to be passed to beneficiaries upon the death of the trustee; (c) pursuant to a court order; (d) by operation of law (including by consolidation or merger) or without consideration in
connection with the dissolution, liquidation or termination of any corporation, limited liability company, partnership or other entity; or (e) as provided in Section 2.8. 

“Phase 3 Clinical Trial” means a human clinical trial of the Milestone Product on sufficient numbers of patients that is designed to
establish that such product is safe and efficacious for its intended use, to evaluate the risk-benefit relationship of the product, and to define warnings, precautions and adverse reactions that 

  
 2 

 
are associated with such product in the dosage range to be prescribed, as described in 21 C.F.R. 312.21(c) (as amended or any replacement thereof), and that is intended to support Regulatory
Authorization of such product or label expansion of such product, or a similar clinical study prescribed by the Regulatory Authorities. For purposes of this Agreement, “commencement” of a Phase 3 Clinical Trial for the Milestone Product
means the first dosing of the Milestone Product in a human in a Phase 3 Clinical Trial for the Milestone Product. 
 “Regulatory Authority”
means any national or supranational Governmental Authority in any Major Market Country that holds responsibility for development and commercialization of, and the granting of regulatory approval or marketing approval for, a biological or
pharmaceutical product, as applicable, in such Major Market Country. 
 “Regulatory Authorization” means any Approval granted by any
Regulatory Authority. 
 “Rights Agent” means the Rights Agent appointed pursuant to the applicable provisions of this Agreement (including
any successor thereto). 
 “Volume Weighted Average Price” for any security as of any trading day means (a) the volume weighted
average sale price of such security on the principal securities exchange on which such security is traded as reported by Bloomberg Financial Markets or an equivalent, reliable reporting service mutually acceptable to and hereinafter designated by UM
(“Bloomberg”), or (b) if no volume weighted average sale price is reported for such security, then the closing price per share of such security as reported by Bloomberg, or, if no closing price per share is reported for such
security by Bloomberg, the average of the last bid and last ask price (or if more than one in either case, the average of the average last bid and average last ask prices) on such trading day as reported in the composite transactions for the
principal U.S. national or regional securities exchange on which such security is traded. 
 SECTION 2 CONTINGENT VALUE RIGHTS 

2.1 CVRs; Appointment of Rights Agent. 

(a) Each Holder shall be entitled to a number of CVRs, if any, calculated as set forth in Section 2.2 and Section 2.3 of the
Merger Agreement. 
 (b) If UM decides to appoint a Rights Agent following the date hereof, UM shall provide the Holder Representative
with written notice of such decision and the identity of a proposed Rights Agent; provided, that the Holder Representative may reasonably object to such proposed Rights Agent within five (5) Business Days of such notice and UM shall be required
to select a different Rights Agent that is reasonably acceptable to the Holder Representative (such acceptance not to be unreasonably withheld, conditioned or delayed). Thereafter, UM and Palladio shall appoint such Rights Agent to act as rights
agent for UM and Palladio in accordance with the terms and conditions set forth in this Agreement, and the Rights Agent shall accept such appointment by executing and delivering a counterpart to this Agreement. If no Rights Agent is appointed,
Palladio or UM, as appropriate, shall take the required actions of the Rights Agent hereunder until a Rights Agent is appointed (including to maintain the CVR Register and pay the Milestone Payments contemplated under Section 2.5). 

(c) The parties acknowledge and agree that in the event it is determined that the CVRs are subject to registration under the Securities
Act or the Exchange Act, the Rights Agent shall be permitted to resign and shall be held harmless for all liabilities in connection therewith. 

  
 3 

 2.2 Nontransferable. The CVRs shall not be sold, assigned, transferred, pledged,
encumbered or in any other manner transferred or disposed of, in whole or in part, other than pursuant to a Permitted Assignment. 
 2.3
No Certificate; Registration; Registration of Transfer; Change of Address. 
 (a) The CVRs shall not be evidenced by a certificate
or other instrument. 
 (b) The Rights Agent shall keep a register (the “CVR Register”) for the purposes of
(i) identifying the Holders of CVRs and (ii) registering CVRs and each Permitted Assignment thereof. The Rights Agent shall promptly update the CVR Register to reflect updated mailing addresses, telephone numbers or email addresses of
Holders provided by Palladio or the Holder Representative. The Holder Representative shall promptly update the Rights Agent and Palladio of any changes to the mailing addresses, telephone numbers or email addresses of any Holder if provided to the
Holder Representative by such Holder. The Rights Agent shall promptly provide a copy of the CVR Register to the Holder Representative upon its written request. 

(c) Subject to the restrictions on transferability set forth in Section 2.2, every request made to transfer a CVR must be in
writing and accompanied by a written instrument of transfer and other requested documentation in form reasonably satisfactory to the Rights Agent, duly executed by the Holder or Holders thereof, or by the duly appointed legal representative,
personal representative or survivor of such Holder or Holders, setting forth in reasonable detail the circumstances relating to the transfer. Upon receipt of such written notice, the Rights Agent shall, subject to its reasonable determination that
the transfer instrument is in proper form and the transfer otherwise complies with the other terms and conditions of this Agreement (including the provisions of Section 2.2), register the transfer of the applicable CVRs in the CVR Register. All
duly transferred CVRs registered in the CVR Register shall be the valid obligations of Palladio or UM, as applicable, evidencing the same right, and shall entitle the transferee to the same benefits and rights under this Agreement, as those held by
the transferor. No transfer of a CVR shall be valid until registered in the CVR Register, and any transfer not duly registered in the CVR Register will be void ab initio. Any transfer or assignment of the CVRs shall be without charge (other than the
cost of any transfer tax) to the applicable Holder. 
 (d) A Holder may make a written request to the Rights Agent to change such
Holder’s address of record in the CVR Register. The written request must be duly executed by the Holder. Upon receipt of such written notice, the Rights Agent shall promptly record the change of address in the CVR Register. 

2.4 Notice and Payment. No later than thirty (30) days after the occurrence of the Milestone Trigger, Palladio shall provide
written notice to the Holder Representative and the Rights Agent of the occurrence of the Milestone Trigger (a “Milestone Statement”), and thereafter UM or Palladio shall deliver to the Rights Agent UM B Ordinary Shares or
cash, respectively, in the aggregate amount of the Milestone Payment in accordance with the procedures set forth in Section 2.5. Palladio shall pay interest on any payments that are not paid on or before the date such payments are due under
this Section 2.5 at an annual rate equal to ten percent (10%) (which shall be added and deemed a part of the Milestone Payment), calculated on the total number of days the payment is delinquent, other than any such payments that are the subject
of a dispute between Palladio, on the one hand, and the Holder Representative or any Holder, on the other hand. 

  
 4 

 2.5 Payment Procedures. 

(a) No later than thirty (30) days following the delivery of the Milestone Statement, the Rights Agent will send a copy of the
current CVR Register to the Holder Representative, which the Holder Representative shall use to determine the Percentage for each Holder and the amount to be paid (in UM B Ordinary Shares or cash, as applicable) to each Holder in respect of the
Milestone Payment. Such amounts shall be reflected in a statement that will promptly be delivered to the Rights Agent, UM and Palladio (the “Payment Statement”). Within ten (10) Business Days of the delivery of the Payment
Statement, on the terms and conditions of this Agreement: 
 (i) if UM has not Divested Palladio prior to the occurrence of the
Milestone Trigger, UM will make appropriate arrangements with the Rights Agent for UM B Ordinary Shares represented by book-entry shares to be issued as the CVR Share Payment. Upon receipt of the book-entry shares referred to in the foregoing
sentence, the Rights Agent shall promptly (and in any event, within ten (10) Business Days) distribute to each Holder by book-entry an amount of UM B Ordinary Shares equal to such Holder’s Percentage multiplied by the CVR Share Payment;
provided, that in lieu of receive a fractional UM B Ordinary Share, such Holder shall be entitled to receive from UM a cash payment equal to such fraction multiplied by the Per Ordinary Share Price; or 

(ii) if UM has Divested Palladio prior to the occurrence of the Milestone Trigger, Palladio shall pay an amount equal to the Milestone
Payment in immediately available funds to the Rights Agent. The Rights Agent shall pay each Holder the amount set forth next to such Holder’s name on the Payment Statement relating to the Milestone Payment as promptly as practicable, but in any
event within ten (10) Business Days of receipt of the Milestone Payment. Payments to be made by Palladio to the Rights Agent hereunder shall be made in U.S. dollars and shall be paid by wire transfer in immediately available funds. Unless
otherwise provided for by the Holder Representative, any payment to a Holder of its portion of the Milestone Payment owed hereunder shall be payable by check to the order of such Person as his, her or its name appears on the CVR Register at the
address listed for such Person in the CVR Register, or at the Right Agent’s election, if such Holder provides wire instructions, by wire transfer. 

The Rights Agent shall promptly, and in any event within ten (10) Business Days after receipt of the Payment Statement under this
Section 2.5(a), send each Holder at its registered address a copy of the Payment Statement. Without limiting any of the rights of the Rights Agent under this Agreement, UM and Palladio shall have no further liability in respect of the CVR Share
Payment upon delivery instructions to the Rights Agents of such CVR Share Payment in accordance with this Section 2.5(a) and the satisfaction of UM’s and Palladio’s obligations set forth in this Section 2.5(a), provided that
Palladio shall be responsible for any failure of the Rights Agents to take, or refrain from taking, any action that the Rights Agents is expected to take, or refrain from taking, to effect the intent of this Section 2.5. For the avoidance of
doubt, the Rights Agent shall not be required at any time to determine the size of any payment to any Holder hereunder and shall be entitled to rely on the Payment Statement in respect of carrying out its obligations hereunder 

(b) The Rights Agent shall promptly send each Holder at its address set forth in the CVR Register a copy of any notice required to be
delivered by Palladio hereunder, including any notice required pursuant to Section 2.5. 

  
 5 

 (c) Except to the extent any portion of the Milestone Payment is required to be
treated as imputed interest pursuant to applicable law or otherwise required by applicable law, the Holders and the parties hereto intend to treat the CVRs and all payments hereunder for all U.S. federal, state, and local income tax purposes as
additional consideration furnished in connection with the Merger. The parties agree, for U.S. federal income tax purposes, to treat cash payments, if any, made pursuant to the CVRs and this Agreement as transfers described in
Section 351(b) of the Code. 
 (d) Notwithstanding any other provision of this Agreement, Palladio, UM, and the Rights Agent
shall be entitled to deduct and withhold from any consideration payable or otherwise deliverable pursuant to this Agreement, such amounts as may be required to be deducted or withheld therefrom under any provision of applicable law. To the extent
such amounts are so deducted or withheld and paid over to the applicable Governmental Authority, such amounts shall be treated for all purposes under this Agreement as having been paid to the Person to whom such amounts would otherwise have been
paid. 
 (e) Any portion of any payment of the Milestone Payment that remains undistributed to the Holders for two (2) years
after the Payment Date shall be delivered by the Rights Agent to Palladio or UM, as applicable, upon demand. 
 (f) Neither Palladio
nor UM nor the Rights Agent shall be liable to any Person in respect of a payment of any portion of the Milestone Payment delivered to a public official pursuant to any applicable abandoned property, escheat or similar legal requirement under
applicable law. If any such payment (or portion thereof) made by Palladio, UM to the Rights Agent remains unclaimed by a Holder two years after the Payment Date (or immediately prior to such earlier date on which such payment would otherwise escheat
to or become the property of any Governmental Authority), any such payment (or portion thereof) shall, to the extent permitted by applicable law, become the property of Palladio or UM, free and clear of all claims or interest of any Person
previously entitled thereto. 
 (g) The Milestone Payment shall be payable one (1) time only and no amounts shall be due for
subsequent or repeated achievements of the Milestone Trigger. 
 2.6 No Voting, Dividends or Interest; No Equity or Ownership Interest in
Palladio or UM. 
 (a) Except for those associated with an actual CVR Share Payment, the CVRs shall not have any voting or
dividend rights, and interest shall not accrue on any amounts payable in respect of the CVRs. 
 (b) Except for those associated with
an actual CVR Share Payment, the CVRs shall not represent any equity or ownership interest in Palladio, UM or any of their respective Affiliates. 

2.7 Ability To Abandon The CVR. The Holder of a CVR may at any time, at such Holder’s option, abandon all of such Holder’s
remaining rights in a CVR by transferring such CVR to Palladio without consideration therefor (the “Abandoned CVRs”). Nothing in this Agreement is intended to prohibit Palladio from offering to acquire CVRs for consideration in its
sole discretion. 
 2.8 Registration on Form S-8. Prior to or concurrently with the
issuance of UM B Ordinary Shares on account of a CVR Share Payment under Section 2.5(a)(i) (or as soon as practicable after it is eligible to do so), if the UM B Ordinary Shares are then traded on a securities exchange, UM shall register on
Form S-8 (or equivalent form) all such UM B Ordinary Shares issuable to the Holders who received CVRs pursuant to Section 2.3(a) to the extent such UM B Ordinary Shares are registrable under Form S-8 under the Securities Act and subject to applicable state blue sky laws (“Covered UM Shares”). UM shall also take such reasonable action as is permitted by applicable law and necessary to ensure
such Covered 

  
 6 

 
UM Shares are free from any sale restrictions arising under any lock-up or market standoff or similar agreement and, to the extent required to satisfy any
withholding obligations of UM (or the applicable payor), facilitate a “sell to cover” arrangement with respect to such Covered UM Shares. 

2.9 Changes in UM B Ordinary Shares. If, as a result of any reorganization, recapitalization, reclassification, or other similar change
in UM’s capital stock, the outstanding UM B Ordinary Shares are exchanged for a different kind, class or series of shares or other securities of UM, an appropriate adjustment to the kind, class or series of shares or other securities subject to
the CVRs and this Agreement shall be made. 
 SECTION 3 THE RIGHTS AGENT 

3.1 Certain Duties And Responsibilities. 

(a) The Rights Agent shall not have any liability for any actions taken or not taken in connection with this Agreement, except to the
extent of its willful misconduct, bad faith or gross negligence. 
 (b) The Rights Agent shall be under no obligation to institute any
action, suit or proceeding, or to take any other action likely to result in the incurrence of material expenses by the Rights Agent, unless Palladio shall furnish the Rights Agent with reasonable security and indemnity for any costs and expenses
that may be incurred. 
 3.2 Certain Rights of Rights Agent. 

(a) The Rights Agent undertakes to perform such duties and only such duties as are specifically set forth in this Agreement, and no
implied covenants or obligations shall be read into this Agreement against the Rights Agent. 
 (b) The Rights Agent may rely and
shall be protected in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order or other paper or document believed by it in good faith to be genuine and to
have been signed or presented by the proper party or parties. 
 (c) Whenever the Rights Agent shall deem it desirable that a matter
be proved or established prior to taking, suffering or omitting any action hereunder, the Rights Agent may, in the absence of bad faith, gross negligence or willful misconduct on its part, rely upon written instructions from Palladio, UM and the
Holder Representative. 
 (d) The Rights Agent may engage and consult with counsel of its selection and the written advice or opinion
of such counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in good faith and in reliance thereon. 

(e) Any permissive rights of the Rights Agent hereunder shall not be construed as a duty. 

(f) The Rights Agent shall not be required to give any note or surety in respect of the execution of such powers or otherwise in respect
of the premises. 
 (g) Palladio agrees    (i) to pay the fees and expenses of the Rights Agent in connection
with the Rights Agent’s performance of its obligations hereunder, as agreed upon in writing by Rights Agent and Palladio on or prior to the date of this Agreement, and (ii) to reimburse the Rights Agent promptly upon demand for all
reasonable and documented out-of-pocket expenses, including all taxes (other than income, receipt, franchise or similar taxes) and governmental charges, incurred by the
Rights Agent in the performance of its obligations under this Agreement. 

  
 7 

 3.3 Resignation and Removal; Appointment of Successor. 

(a) The Rights Agent may resign at any time by giving written notice thereof to UM, Palladio and the Holder Representative specifying a
date when such resignation shall take effect, which notice shall be sent at least 30 days prior to the date so specified (or, if earlier, the appointment of the successor Rights Agent). 

(b) UM shall have the right to remove the Rights Agent at any time by written instruction signed by an officer of UM specifying a date
when such removal shall take effect. Notice of such removal shall be given by UM to Rights Agent and the Holder Representative, which notice shall be sent at least 60 days prior to the date so specified (or, if earlier, the appointment of the
successor Rights Agent). 
 (c) If the Rights Agent shall resign, be removed or become incapable of acting, UM shall, with the prior
written consent of the Holder Representative (not to be unreasonably withheld, conditioned or delayed), promptly appoint a successor Rights Agent. The successor Rights Agent so appointed shall, forthwith upon its acceptance of such appointment in
accordance with this Section 3.3(c) and Section 3.4, become the successor Rights Agent for all purposes hereunder. 
 (d)
Any Person into which the Rights Agent may be merged or with which it may be consolidated, or any Person resulting from any merger, conversion or consolidation to which the Rights Agent shall be a party, or any Person succeeding to the payments
business of the Rights Agent, shall be the successor to the Rights Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto. 

(e) Palladio shall give notice of each resignation or removal of the Rights Agent and each appointment of a successor Rights Agent by
mailing written notice of such event by first-class mail, postage prepaid, to the Holder Representative. Each notice shall include the name and address of the successor Rights Agent. If Palladio fails to send such notice within ten
(10) Business Days after acceptance of appointment by a successor Rights Agent, the successor Rights Agent shall cause the notice to be mailed at the expense of Palladio. 

(f) Notwithstanding anything to the contrary in this Section 3.3, unless consented to in writing by the Holder Representative, UM
shall not appoint as a successor Rights Agent any Person that is not a paying agent of national reputation. 
 3.4 Acceptance of
Appointment By Successor. Every successor Rights Agent appointed hereunder shall, at or prior to such appointment, execute, acknowledge and deliver to UM, Palladio, the Holder Representative and to the retiring Rights Agent an instrument
accepting such appointment and a counterpart of this Agreement, and thereupon such successor Rights Agent, without any further act, deed or conveyance, shall become vested with all the rights, powers, trusts and duties of the retiring Rights Agent;
provided, that upon the request of UM, Palladio, the Holder Representative or the successor Rights Agent, such resigning or removed Rights Agent shall execute and deliver an instrument transferring to such successor Rights Agent all the rights,
powers and trusts of such resigning or removed Rights Agent. 

  
 8 

 SECTION 4 COVENANTS 

4.1 List of Holders; Delivery of Closing Date Allocation Schedule. As of the date hereof, Palladio has furnished or caused to be
furnished to the Rights Agent the Allocation Schedule. The Allocation Schedule shall set forth the allocation of the CVRs issued under the Merger Agreement. 

4.2 Payment of Milestone Payment. UM or Palladio, as applicable, shall duly and promptly deposit with the Rights Agent for payment to
the Holders, the Milestone Payment, if any, in the manner provided for in Section 2.5 and in accordance with the terms of this Agreement. 

4.3 Status Meetings. During the Milestone Period, upon the written request of the Holder Representative, Palladio agrees to meet with
the Holder Representative, or its designee(s), at a mutually convenient time during normal business hours for the purpose of discussing the status of development activities toward achievement of the Milestone Trigger; provided, however, that the
Holder Representative shall not request such meetings, and Palladio shall have no obligation to attend any such meetings, more than two times during any calendar year. Each such meeting shall be held either telephonically, by video conference or at
Palladio’s offices. 
 4.4 Divestitures. If at any time after the Closing, (a) Palladio Divests the Milestone Product to a
Person that is not an Affiliate of UM and the corresponding intellectual property (collectively, the “Divested Assets” and the party acquiring the Divested Assets or Palladio, the “Transferee”), Palladio shall make
provision for the Transferee to assume and succeed to the obligations of Palladio set forth in this Agreement, or (b) UM Divests Palladio to a Transferee, notwithstanding anything to the contrary set forth herein, UM shall have no further
obligations hereunder (including to issue the CVR Share Payment) and all obligations hereunder shall be fulfilled by such Transferee (or Palladio in the case of a Divestiture of Palladio) and the Milestone Payment shall be payable in cash (rather
than the CVR Share Payment). The Transferee shall properly complete and deliver to the Rights Agent any know-your-customer or similar documentation required under applicable laws and regulations. 

4.5 Milestone Trigger Disputes. UM shall, and shall cause Palladio to, promptly provide such information as may reasonably requested by
the Holder Representative from time to time to assess whether the Milestone Trigger has occurred. If the Holder Representative believes that the Milestone Trigger has occurred, or that the Milestone Statement is inaccurate in whole or in part, then
the Holder Representative shall deliver to Palladio written notice thereof (a “Milestone Dispute Notice”), in reasonable detail. During the thirty (30) days following the delivery of a Milestone Dispute Notice, Palladio and the
Holder Representative shall attempt in good faith to resolve any dispute as to whether the Milestone Trigger has occurred and whether the Milestone Payment is payable. If Palladio and the Holder Representative do not reach agreement with respect to
any dispute relating to any such matter within thirty (30) days after a Milestone Dispute Notice is delivered to Palladio by the Holder Representative, the parties shall submit for arbitration all matters that remain in dispute and that were
properly included in the Milestone Dispute Notice to a disinterested individual who has appropriate scientific, technical and regulatory expertise (as relevant) to resolve any disputes referred to him or her under this Agreement who is mutually
agreed to by Palladio and the Holder Representative (a “Scientific Expert”); provided, however, that such Scientific Expert shall not be or have been at any time within the previous five (5) years an Affiliate, employee,
consultant, officer or director of UM, the Holder Representative, Palladio, any Holder or any of their respective Affiliates. If Palladio and the Holder Representative cannot agree on a mutually acceptable Scientific Expert within thirty
(30) days after either party has determined that the parties cannot reach agreement with respect to a dispute, then within five (5) Business Days after the expiration of such thirty (30) day period, each of Palladio and the Holder
Representative shall appoint one Scientific Expert who shall jointly select a third Scientific Expert within five (5) Business Days after the last to occur of their respective appointments to arbitrate the referred matter. The Scientific Expert
mutually 

  
 9 

 
agreed by the parties or, if the parties cannot agree, the third Scientific Expert selected by the party-appointed Scientific Experts is referred to as the “Selected Scientific
Expert”. Palladio and the Holder Representative shall instruct the Selected Scientific Expert to determine as promptly as practicable but in no event later than thirty (30) days after such person’s appointment (the
“Determination Period”) whether the disputed Milestone Trigger has occurred. The Selected Scientific Expert’s determination shall be made based on the submission of documents and evidence by the parties (including any such
documentation or evidence reasonably requested by the Selected Scientific Expert, which the Holder Representative or Palladio shall provide upon request) and, upon the Selected Scientific Expert’s request, by third parties, unless the Selected
Scientific Expert determines that an oral hearing is necessary. The Selected Scientific Expert shall determine deadlines (which Palladio and the Holder Representative shall deem to be fair and appropriate) within the Determination Period for
submitting documents and dates, if any, of oral hearings. Each of Palladio and the Holder Representative (on behalf of the Holders) shall pay its own expenses of arbitration, and the fees, costs and expenses of the Selected Scientific Expert
initially shall be equally shared between Palladio and the Holder Representative (on behalf of the Holders), provided that the prevailing party’s out-of-pocket
expenses in such dispute (including its share of the arbitration, its attorneys’ fees, costs and expenses actually incurred, and the fees, costs and expenses of the Selected Scientific Expert) shall be reimbursed by the other party. Any
decision rendered by the Selected Scientific Expert shall be final and binding upon the parties. All proceedings conducted by the Selected Scientific Expert shall take place in New York, New York. Any underpayments of Milestone Payments shall be
paid by Palladio to the Rights Agent within fifteen (15) Business Days of notification of the final determination of the Milestone Dispute Notice in accordance with this Agreement (and the Rights Agent shall subsequently make all payments
required by and in accordance with Section 2.5(a) hereof). 
 4.6 Post-Closing Development. Notwithstanding anything contained
herein or in the Merger Agreement, subject to the Portfolio Company Agreement and UM’s obligation to fund and support Palladio in accordance with the terms contained therein, following the date hereof, (i) Palladio shall have the right to
own, operate, use, license, develop and otherwise commercialize its assets, including the Milestone Product and its related intellectual property, in any way that Palladio deems appropriate, in its sole discretion, (ii) Palladio shall not have
any obligation to own, operate, use, license, develop or otherwise commercialize its assets, including the Milestone Product and its related intellectual property, in order to maximize or expedite the Milestone Payment, (iii) Palladio shall
have the exclusive right to determine the terms and conditions of the development and commercialization of its assets, including the Milestone Product, and any and all sales of the Milestone Product, including the determination of whether to develop
or commercialize or whether to terminate the development of the Milestone Product, or the indications for which the Milestone Product may be developed or commercialized, (iv) there is no assurance that the Holders will receive the Milestone
Payment, (v) Palladio has not, prior to, or after the date hereof, promised or projected any amounts to be received by the Holders in respect of the Milestone Payment, and neither the Rights Agent nor any Holder has, prior to or after the
Closing Date, relied on any statements or information provided by or on behalf of Palladio or UM with respect to the potential sales or value of the Milestone Product and (vi) the parties and the Holders intend the express provisions of this
Agreement to govern their contractual relationship and to supersede any standard of efforts or implied covenant of good faith and fair dealing that might otherwise be imposed by any court or other Governmental Authority or otherwise; provided that
UM shall not, and shall cause Palladio not to, take any action, or refrain from taking any action the sole purpose of which is to frustrate the ability to achieve the Milestone Trigger or the Milestone Payment. 

4.7 Lock Up. Each Holder (and any UM Ordinary Shares issued on account of a CVR Share Payment under Section 2.5(a)(i)) shall be
subject to the lock up and related obligations contemplated by Clause 41 of the UM Articles as if they were Shareholders (as defined in the UM Articles), subject to Section 2.8 in the case of the Covered UM Shares. 

  
 10 

 SECTION 5 AMENDMENTS 

5.1 Amendments Without Consent of Holders or Rights Agent. 

(a) UM and Palladio, at any time and from time to time, may unilaterally enter into one or more amendments hereto, for any of the
following purposes, without the consent of any of the Holders (including the Holder Representative) or the Rights Agent, so long as, in the cases of clauses (ii) through (iv), such amendments do not adversely affect the interests of the
Holders: 
 (i) to evidence the appointment of another Person as a successor Rights Agent and the assumption by any successor Rights
Agent of the covenants and obligations of the Rights Agent herein in accordance with the provisions hereof; 
 (ii) to add to the
covenants of Palladio such further covenants, restrictions, conditions or provisions as Palladio shall determine to be for the protection of the Holders; 

(iii) to cure any ambiguity, to correct or supplement any provision herein that may be defective or inconsistent with any other
provision herein, or to make any other provisions with respect to matters or questions arising under this Agreement; or 
 (iv) as
may be necessary to ensure that the CVRs are not subject to registration under the Securities Act or the Exchange Act. 
 (b) Promptly
after the execution by Palladio of any amendment pursuant to the provisions of this Section 5.1, Palladio shall mail (or cause the Rights Agent to mail) a notice thereof by first class mail to the Holders at their addresses as they shall appear
on the CVR Register and to the Holder Representative, setting forth in general terms the substance of such amendment. 
 5.2 Amendments
With Consent of Holders. 
 (a) In addition to any amendments to this Agreement that may be made by UM and Palladio without the
consent of any Holder (or the Holder Representative) or the Rights Agent pursuant to Section 5.1, UM, Palladio, the Holder Representative and the Rights Agent may enter into one or more amendments hereto for the purpose of adding, eliminating
or changing any provisions of this Agreement, even if such addition, elimination or change is adverse to the interests of the Holders. 

(b) Promptly after the execution by UM, Palladio, the Holder Representative and the Rights Agent of any amendment pursuant to the
provisions of this Section 5.2, Palladio shall mail (or cause the Rights Agent to mail) a notice thereof by first class mail to the Holders at their addresses as they shall appear on the CVR Register, setting forth in general terms the
substance of such amendment. 
 5.3 Execution of Amendments. In executing any amendment permitted by this Section 5, the Rights
Agent shall be entitled to receive, and shall be fully protected by Palladio in relying upon, an opinion of counsel selected by Palladio stating that the execution of such amendment is authorized or permitted by this Agreement. The Rights Agent may,
but is not obligated to, enter into any such amendment that affects the Rights Agent’s own rights, privileges, covenants or duties under this Agreement or otherwise. 

5.4 Effect of Amendments. Upon the execution of any amendment under this Section 5, this Agreement shall be modified in accordance
therewith, such amendment shall form a part of this Agreement for all purposes and every Holder shall be bound thereby. 

  
 11 

 SECTION 6 MISCELLANEOUS PROVISIONS 

6.1 Entire Agreement; Counterparts. This Agreement, the other Transaction Documents and all other agreements contemplated hereby sets
forth the entire understanding of the parties hereto with respect to the transactions contemplated hereby. Any and all previous agreements and understandings between or among the parties regarding the subject matter hereof, whether written or oral,
are superseded by this Agreement. This Agreement may be executed in one or more counterparts, delivered by original, facsimile signature or emailed .PDF attachment, all of which together shall constitute one and the same instrument and shall become
effective when one or more counterparts have been signed by each of the parties hereto and delivered to the other parties hereto; it being understood that all parties hereto need not sign the same counterpart. 

6.2 Notices To Rights Agent, Holder Representative, UM and Palladio. All notices and other communications given or made pursuant hereto
shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by electronic mail if sent during normal business hours of the recipient, if not during normal business
hours, then on the next day, (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one (1) day after deposit with a nationally recognized overnight courier,
specifying next day delivery, with written verification of receipt. All communications shall be sent to the respective parties at the following addresses (or at such other addresses as shall be specified by notice given in accordance with this
Section 6.2): 
 If to Palladio or UM: 

United Medicines Biopharma Limited 

The Dorothy Hodgkin Building, Babraham Research Campus 

Cambridge, UK CB22 3FH 

Attention: Saurabh Saha, CEO 

with a copy (which shall not constitute notice to): 

GOODWIN PROCTER LLP 
 100
Northern Avenue 
 Boston, Massachusetts 02210 

Attention: Mitch Bloom 
 Email:
mbloom@goodwinlaw.com 
 If to the Holder Representative: 

628 Middlefield Road 
 Palo
Alto, CA 94301 
 Attention: Srinivas Akkaraju, MD, PhD 

Email: srini@samsaracap.com 

6.3 Notice To Holders. Where this Agreement provides for notice to Holders, such notice shall be sufficiently given (unless otherwise
herein expressly provided) if in writing and mailed, first-class postage prepaid, to each Holder affected by such event, at his, her or its address as it appears in the CVR Register, not later than the latest date, and not earlier than the earliest
date, prescribed for the giving of such notice. In any case where notice to Holders is given by mail, neither the failure to mail such notice, nor any defect in any notice so mailed, to any particular Holder shall affect the sufficiency of such
notice with respect to other Holders. 

  
 12 

 6.4 Successors and Assigns; Assignability. This Agreement shall be binding upon, and
shall be enforceable by and inure solely to the benefit of, the parties hereto and their respective successors and assigns. The Rights Agent may not assign this Agreement without Palladio’s prior written consent. Except in connection with a
Divestiture as contemplated by Section 4.6, neither Palladio nor UM may assign or transfer this Agreement or any of its rights and obligations hereunder, in whole or in part (whether by operation of law or otherwise), without the prior written
consent of the Holder Representative. Any attempted assignment of this Agreement or any of such rights in violation of this Section 6.4 or Section 2.2 shall be void and of no effect. 

6.5 Benefits of Agreement. Nothing in this Agreement, express or implied, shall give to any Person (other than the parties hereto, the
Holders and their permitted successors and assigns hereunder) any rights, remedies, benefits, obligations, liabilities or claims under this Agreement or under any covenant or provision herein contained, all such covenants and provisions being for
the sole benefit of the parties hereto, the Holders and their permitted successors and assigns. The rights of Holders with respect to the CVRs are limited to those expressly provided in this Agreement. 

6.6 Governing Law; Jurisdiction. This Agreement shall be governed by and construed and enforced in accordance with the laws of the
State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws thereof. Subject to Section 4.5 of this Agreement, Section 6.8 of the Merger Agreement is hereby incorporated herein
mutatis mutandis. 
 6.7 WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY
JURY IN ANY LEGAL PROCEEDING BETWEEN THE PARTIES HERETO ARISING OUT OF OR RELATING TO THIS AGREEMENT. 
 6.8 Legal Holidays. In the
event that the Payment Date shall not be a Business Day, then, notwithstanding any provision of this Agreement to the contrary, any payment required to be made in respect of the CVRs on such date need not be made on such date, but may be made on the
next succeeding Business Day with the same force and effect as if made on the Payment Date. 
 6.9 Severability. If any provision of
this Agreement is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Agreement shall remain in full force and effect. The parties further agree that if any provision contained herein is, to any extent,
held invalid or unenforceable in any respect under the laws governing this Agreement, they shall take any actions necessary to render the remaining provisions of this Agreement valid and enforceable to the fullest extent permitted by law and, to the
extent necessary, shall amend or otherwise modify this Agreement to replace any provision contained herein that is held invalid or unenforceable with a valid and enforceable provision giving effect to the intent of the parties. 

6.10 Termination. This Agreement shall be terminated and of no force or effect, the parties hereto shall have no liability hereunder,
and no payments shall be required to be made, upon the earliest to occur of (a) payment of the Milestone Payment to the Holders under the terms of this Agreement, and (b) the fifth (5th)
anniversary of the Closing Date. The termination of this Agreement shall not affect or limit the right to receive any payment of the Milestone Payment hereunder to the extent earned prior to termination of this Agreement and the provisions
applicable thereto shall survive the expiration or termination of this Agreement. 
 This Agreement shall automatically terminate upon the
termination of the Framework Agreement in accordance with clause 10.2 thereof, with the consequences of such termination to be as exclusively set forth in clause 10.3 thereof. 

  
 13 

 6.11 Construction; Guaranty. Section 6.10 of the Merger Agreement is hereby
incorporated herein mutatis mutandis. UM guarantees to the Holders the due and punctual payment of Palladio’s payment obligations under this Agreement until a Divestiture in accordance with Section 4.6 (after which, this sentence
shall automatically terminate upon the consummation of such Divestiture). 
 6.12 Holder Representative.    Srini
Akkaraju is hereby appointed as of the date hereof as the agent and attorney in fact of the Holders as the Holder Representative for and on behalf of the Holders to give and receive notices and communications in connection with this Agreement and
related matters and to agree to, negotiate, and enter into settlements, adjustments and compromises of, and make and defend claims and comply with orders of courts and awards with respect to such claims, and to take all other actions that are
either (i) necessary or appropriate in the judgment of the Holder Representative for the accomplishment of the foregoing or (ii) permitted by the terms of this Agreement. Such agency may be changed by the Holders from time to time upon not
less than ten (10) days prior written notice to the other parties hereto; provided, that the Holder Representative may not be removed unless Holders holding a majority of the CVRs agree in writing to such removal and to the identity of the
substituted agent. A vacancy in the position of the Holder Representative may be filled by written appointment by Holders holding a majority of the CVRs. No bond shall be required of the Holder Representative. Notices or communications to or from
the Holder Representative shall constitute notice to or from the Holders. A decision, act, consent or instruction of the Holder Representative shall constitute a decision of all or any portion of the Holders and shall be final, binding and
conclusive upon each of them. The other parties hereto are entitled to rely upon any notice provided to or communication with any such party and any such decision, act, consent or instruction of the Holder Representative as being the decision, act,
consent or instruction of all or any portion of the Holders. The other parties hereto are hereby relieved from any liability to any Person for any acts done by such party in accordance with such decision, act, consent or instruction of the Holder
Representative. 
 6.13 Section 409A. The Parties acknowledge that payments pursuant to any the CVRs granted in
respect of any Palladio Options as contemplated hereunder shall be deemed to be subject to a “substantial risk of forfeiture” within the meaning of Section 409A of the Code as of the date hereof, and all provisions regarding all
payments to be made hereunder shall be interpreted in such a manner consistent with such intent. Further, all payments with respect to any CVRs held by the former holders of Palladio Options shall be made no later than March 15 of the calendar
year following the calendar year in which such substantial risk of forfeiture lapses. 
 [Signature Page Follows] 

  
 14 

 IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed on its behalf by its duly
authorized officers as of the day and year first above written. 
  

			
	PALLADIO BIOSCIENCES, INC.
		
	By:	 	  

		 	Name:
		 	Title:
	
	SRINI AKKARAJU, solely in his capacity as the Holder Representative
		
	By:	 	  

		 	Name:
	
	UNITED MEDICINES BIOPHARMA LIMITED
		
	By:	 	  

		 	Name:
		 	Title:EX-10.13

 Exhibit 10.13 

[####] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed. 
 Private & Confidential 

Dated                      
              23 January 2021 
 APCINTEX LIMITED 

AND 
 THE SELLERS

 AND 
 UNITED
MEDICINES BIOPHARMA LIMITED 
 CONTRIBUTION AGREEMENT 
  

 
  

 TABLE OF CONTENTS 

 

							
	 	  	Page	 
	 1.
	 	DEFINITIONS AND INTERPRETATION	  	 	1	 
			
	 2.
	 	CONTRIBUTION	  	 	7	 
			
	 3.
	 	COMPLETION	  	 	8	 
			
	 4.
	 	CONDITION	  	 	8	 
			
	 5.
	 	UM WARRANTIES	  	 	9	 
			
	 6.
	 	FUNDAMENTAL WARRANTIES	  	 	10	 
			
	 7.
	 	WARRANTIES AND LIABILITY	  	 	11	 
			
	 8.
	 	LIMITATIONS ON CLAIMS	  	 	12	 
			
	 9.
	 	TAX	  	 	13	 
			
	 10.
	 	CONFIDENTIALITY	  	 	13	 
			
	 11.
	 	ANNOUNCEMENTS	  	 	14	 
			
	 12.
	 	FURTHER ASSURANCE	  	 	15	 
			
	 13.
	 	EFFECT OF COMPLETION	  	 	15	 
			
	 14.
	 	COSTS	  	 	15	 
			
	 15.
	 	CUMULATIVE REMEDIES	  	 	15	 
			
	 16.
	 	WAIVER	  	 	15	 
			
	 17.
	 	ENTIRE AGREEMENT	  	 	15	 
			
	 18.
	 	VARIATION	  	 	16	 
			
	 19.
	 	NO PARTNERSHIP	  	 	16	 
			
	 20.
	 	ASSIGNMENT AND TRANSFER	  	 	16	 
			
	 21.
	 	RIGHTS OF THIRD PARTIES	  	 	16	 
			
	 22.
	 	COUNTERPARTS; NO ORIGINALS	  	 	16	 
			
	 23.
	 	NOTICES	  	 	17	 
			
	 24.
	 	SEVERANCE	  	 	17	 
			
	 25.
	 	GOVERNING LAW	  	 	17	 
			
	 26.
	 	JURISDICTION	  	 	17	 
		
	 SCHEDULE 1 : SELLERS
	  	 	18	 
		
	 SCHEDULE 2 : COMPLETION OBLIGATIONS
	  	 	20	 
		
	 SCHEDULE 3 : WARRANTIES
	  	 	22	 
		
	 SCHEDULE 4 : UM CAPITALISATION TABLE
	  	 	39	 
		
	 SCHEDULE 5 : PARTICULARS OF THE COMPANY
	  	 	41	 

  
 -i- 

 THIS CONTRIBUTION AGREEMENT (this “Agreement”) is made on 23 January 2021

 BETWEEN: 
  

	(1)	 APCINTEX LIMITED, a private company limited by shares incorporated in England with company number
09088717 with its registered office at C/O Medicxi, 25 Great Pulteney Street, London, England, W1F 9LT (the “Company”); 

  

	(2)	 THE SELLERS whose names and addresses are set out in columns (1) and (2) of Schedule 1
(together the “Sellers”, and each a “Seller”); and 

  

	(3)	 UNITED MEDICINES BIOPHARMA LIMITED, a private company limited by shares incorporated in England
with company number 12973576 and with its registered office at The Dorothy Hodgkin Building, Babraham Research Campus, Babraham, Cambridge, United Kingdom, CB22 3FH (“UM”), 

(each a “Party” and together, the “Parties”). 

WHEREAS: 
 In accordance with the terms of
this Agreement, the Parties agree that each Seller will transfer to UM the Sale Shares set opposite such Seller’s name in column (4) of Schedule 1, and UM shall purchase from the Sellers all such Sale Shares, which together constitute the
entire issued share capital of the Company, in exchange for the issue of the UM Shares (as defined below) to each Seller in such number as set out opposite their respective names in column (5) of Schedule 1. 

IT IS AGREED as follows: 
  

	1.	 DEFINITIONS AND INTERPRETATION 

 

	1.1	 The following words and expressions used in this Agreement have the meanings given to them below:

  

			
	Act	  	means the Companies Act 2006, as amended and/or superseded from time to time;
		
	Affiliate	  	means, in relation to a Person, any Person or other business entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with such Person or any venture capital
fund now or hereafter existing that is controlled by or under common control with one or more general partners or managing members of, or shares the same management or advisory company with, such Person. For purposes of this definition, the term
“control” (including, the correlative meanings, “controlled by” and “under common control with”) means:
		
		  	 (a)   the direct or indirect ownership of more than 50% of the stock having
the right to vote for directors thereof (or general partnership interests); or

		
		  	 (b)   the ability to otherwise control the decisions of the board of
directors or equivalent governing body thereof;

		
	Applicable Law(s)	  	means all laws, regulations, directives, statutes, subordinate legislation, common law and civil codes of any jurisdiction, all judgments, orders, notices, instructions, decisions and awards of any court or competent authority or
tribunal and all codes of practice having force of law, statutory guidance and policy notes;

  
 1 

			
		
	A Preference Shares	  	means A preference shares of £0.0001 each in the share capital of the Company having the rights given to them in the articles of association of the Company;
		
	Board	  	means the board of directors of UM;
		
	B Preference Shares	  	means B preference shares of £0.0001 each in the share capital of the Company having the rights given to them in the articles of association of the Company;
		
	Business	  	means the business of the research and development of a new therapy for haemophilia, as more fully described in the Business Plan;
		
	Business Day	  	means a day (which is not a Saturday, Sunday or a public or bank holiday in the following location) on which banks generally are open in the City of London (England);
		
	Business Plan	  	means the business plan of the Company in the agreed form and attached to the Portfolio Company Agreement;
		
	Claim	  	means any claim for Loss as a result of any breach of Warranty;
		
	Company Resolutions	  	means the resolutions in the agreed form to be passed by the members of the Company by written resolution in order to adopt the New Articles;
		
	Completion	  	means the completion of the sale and purchase of the Sale Shares in accordance with clauses 2 and 3;
		
	Completion Date	  	means the date on which Completion occurs;
		
	Condition	  	means the delivery of the UM Confirmation (as defined in the Framework Agreement) to the Company in accordance with the Framework Agreement;
		
	Confidential Information	  	means all information (whether oral or recorded in any medium) relating to the Business, financial or other affairs (including future plans and targets of any Group Company) which is treated as confidential by any Group Company or
is by its nature confidential or which is not in the public domain;
		
	Constitution	  	has the meaning given in section 17 of the Act;
		
	Contribution	  	has the meaning given in clause 2.1;
		
	CTA 2010	  	means the Corporation Tax Act 2010;
		
	Deed of Termination	  	means the deed of termination (in the agreed form) terminating the Existing Agreements;
		
	Director Deed of Indemnity	  	means the deed of indemnity (in the agreed form) to be entered into at Completion by the Company with each New Director;
		
	Disclosed	  	means fairly disclosed to UM in the Disclosure Letter, with sufficient explanation and detail to enable UM to identify the nature, scope and implications of the matters disclosed;
		
	Disclosure Letter	  	means the letter in the agreed form from the Warrantors to UM disclosing certain matters relating to certain of the Warranties dated on or before the date of this Agreement;
		
	Encumbrance	  	means any mortgage, charge, security interest, lien, pledge, assignment by way of security, equity, claim, right of pre-emption, option, covenant, restriction, reservation, lease, trust,
order, decree, judgment, title defect (including retention of title claim), conflicting claim of ownership or any other encumbrance of any nature whatsoever (whether or not perfected other than liens arising by operation of
law);

  
 2 

			
	 Existing Agreements
	  	means:
		
		  	 (a)   the shareholders’ agreement relating to the Company dated
7 October 2020 entered into between the Company and the Shareholders (as defined therein); and
  

(b)   the investment agreement relating to the Company dated 7 October 2020 entered into between
(i) Medicxi Secondary, (ii) Medicxi Co-Invest, (iii) IP2IPO, (iv) the Founders (each as defined therein), and (v) the Company;

		
	 Financing
	  	has the meaning given in the Framework Agreement;
		
	 Framework Agreement
	  	means the framework agreement to be entered into on or around the date of this Agreement between, inter alia, the Company and UM;
		
	 Fully Diluted Share Capital
	  	means the aggregate at the time of (in each case on an as converted basis): (a) the issued share capital of UM; and (b) all shares capable of being issued by UM pursuant to any outstanding rights to subscribe for, or convert
any security into, shares as if all those outstanding rights had been exercised in full (including, without limitation, all shares capable of being issued by UM in respect of unallocated and/or unvested options);
		
	 Fundamental Warranty
	  	means:
		
		  	 (a)   in respect of the Sellers (including, for the avoidance of doubt, the
Warrantors), the warranties set forth in clause 6.1 other than clause 6.1(j);

		
		  	 (b)   in respect of those Sellers who are Warrantors, in addition to (a)
above, the warranty set forth in clause 6.1(j); and

		
		  	 (c)   in respect of UM, the warranties set forth in clause 5;

		
	 Fundamental Warranty Claim
	  	means any claim for breach of any Fundamental Warranty;
		
	 Governmental Authority
	  	means any foreign or domestic national, supranational, state, federal, provincial, local, or similar government, governmental, regulatory or administrative authority, agency or commission, or any court, agency or other body,
organisation, group, stock market or exchange exercising any executive, legislative, judicial, quasi-judicial, regulatory or administrative function of government;
		
	 Group Companies
	  	means the Company and each and any of its subsidiaries from time to time, and “Group Company” shall mean any one of them;
		
	 HMRC
	  	means HM Revenue & Customs;
		
	 IPO
	  	means the admission of (or in the case of admission to NASDAQ, the initial public offering of) all or any of the UM Shares or securities representing those shares (including without limitation depositary interests, American
depositary receipts, American depositary shares and/or other instruments) on NASDAQ or the New York Stock Exchange or the Official List of the United Kingdom Listing Authority or the AIM Market operated by the London Stock Exchange or any other
recognised investment exchange (as defined in section 285 of the Financial Services and Markets Act 2000);

  
 3 

			
	Key Persons	  	[####]
		
	Longstop Date	  	means 5 February 2021 (or such later date as provided for in the Framework Agreement);
		
	Loss	  	means the diminution in the value of the Sale Shares or UM Shares (as applicable);
		
	Material Contract	  	means any written contract which a Group Company needs to remain in force in order that it can carry on its business in a manner that is not adverse to the current or future prospects of its business, an exhaustive list of such
contracts being appended to the Disclosure Letter;
		
	NASDAQ	  	means the NASDAQ Stock Market of the NASDAQ OMX Group Inc.;
		
	New Articles	  	means the articles of association of the Company (in the agreed form) to be adopted on or before Completion;
		
	New Directors	  	means such persons notified by UM to the Company prior to Completion;
		
	Ordinary Shares	  	means the B ordinary shares in the share capital of UM having the rights given to them in the articles of association of UM;
		
	Permitted Assignee	  	has the meaning given in clause 20.2;
		
	Person	  	has the meaning given in clause 1.2(a);
		
	Portfolio Company Agreement	  	means the agreement relating to the Company to be entered into at Completion by UM, the Company and the Initial Leadership Team (as defined therein), in the agreed form;
		
	Power of Attorney	  	means an irrevocable power of attorney (in the agreed form) in favour of the directors of UM in respect of the performance by the principal of its obligations under the articles of association of UM in connection with or otherwise
ancillary to an IPO;
		
	Preference Seller	  	means any Seller whose shares in the Company on the date of this Agreement include A Preference Shares or B Preference Shares;
		
	Relevant Claim	  	means a Claim or Fundamental Warranty Claim;
		
	Relevant Persons	  	 [####] 
 [####]

[####];

		
	Resigning Directors	  	means James Huntington, Trevor Baglin, Kevin Johnson and IP2IPO Services Limited;
		
	Sale Shares	  	means those shares in the Company set out in column (4) of Schedule 1;
		
	Sellers’ Majority	  	means Sellers representing not less than 90% of the total voting rights of the Company immediately prior to Completion;
		
	Taxation	  	means all forms of taxation, duties, rates, levies, contributions, withholdings, deductions, liabilities to account, charges and imposts whether imposed in the United Kingdom or elsewhere in the world and any interest, fines,
penalties, assessments or additions to tax imposed with respect thereto;

  
 4 

			
	 Tax Authority
	  	means HMRC and any other governmental state, federal, provincial, local governmental or municipal authority, body or official whether of the United Kingdom or elsewhere in the world, which is competent to impose or collect
Taxation;
		
	 Transaction Documents
	  	means this Agreement, the Framework Agreement, the UM Shareholders’ Agreement, the Portfolio Company Agreement and those other documents referred to herein which are to be entered into on or before Completion in connection with
the sale and purchase of the Sale Shares;
		
	 UM Articles
	  	means the articles of association of UM to be adopted by UM in connection with the Financing on or about Completion (in the agreed form);
		
	 UM Resolutions
	  	means the resolutions in the agreed form to be passed by the members of UM by written resolution in order to (amongst others):
		
		  	 (a)   authorise the allotment of the UM Shares; and

		
		  	 (b)   waive pre-emption rights in
respect of the allotment and issue of the UM Shares;

		
	 UM Shareholders’ Agreement
	  	means the shareholders’ agreement relating to UM to be entered into on or about Completion, in the form agreed between UM and those Sellers that are required to enter into such agreement at Completion;
		
	 UM Shares
	  	means those Ordinary Shares set out in column (5) of Schedule 1;
		
	 Voting Power of Attorney
	  	means an irrevocable voting power of attorney (in the agreed form) in favour of UM;
		
	 Warranties
	  	means the warranties given pursuant to clause 7 (references to a particular “Warranty” being, unless otherwise specified, to a statement set out in Schedule 3); and
		
	 Warrantors
	  	means each of the Key Persons, but, for the avoidance of doubt, excluding any other Seller.

  

	1.2	 In this Agreement, unless expressly stated otherwise or the context otherwise requires: 

 

	 	(a)	 references to a “Person” shall include any natural person, individual, company, unincorporated
association, firm, corporation, partnership, limited liability company, trust, joint venture or consortium, government, state or agency of a state, and any undertaking (in each case, whether or not having separate legal personality and irrespective
of the jurisdiction in or under the laws of which it was incorporated or exists); 

  

	 	(b)	 references to a “company” shall include any company, corporation or any body corporate (in
each case, irrespective of the jurisdiction in or under the laws of which it was incorporated or exists); 

  

	 	(c)	 references to one gender shall include all genders and references to the singular shall include the plural and
vice versa; 

  

	 	(d)	 a Person shall be deemed to be connected with another if that Person is connected with such other within the
meaning of section 1122 of CTA 2010; 

  
 5 

	 	(e)	 the words subsidiary, holding company, subsidiary undertaking, parent undertaking, undertaking and group shall
have the same meaning in this Agreement as in the Act; 

  

	 	(f)	 references to a statute or statutory provision shall include: 

 

	 	(i)	 that statute or provision as from time to time amended, modified,
re-enacted or consolidated whether before or after the date of this Agreement; 

  

	 	(ii)	 any past statute or statutory provision as from time to time amended, modified,
re-enacted or consolidated which that statute or provision has directly or indirectly replaced; and 

  

	 	(iii)	 any subordinate legislation made from time to time under that statute or statutory provision;

  

	 	(g)	 references to any English legal term (including any statute, regulation,
by-law or other requirement of English law) shall, in respect of any jurisdiction other than England, be construed as references to the term or concept which most nearly corresponds to it in that jurisdiction;

  

	 	(h)	 references to any time of day or date shall be construed as references to the time or date prevailing in
London, England; 

  

	 	(i)	 references to this Agreement shall include the Schedules (and the Schedules form part of the operative
provisions of this Agreement and shall have the same force and effect as if expressly set out in the body of this Agreement); 

  

	 	(j)	 references herein to clauses, Schedules, paragraphs or Parts are (unless otherwise stated) to clauses of and
schedules to this Agreement and to paragraphs and parts of the Schedules; 

  

	 	(k)	 the table of contents and the clause and paragraph headings in this Agreement are for convenience only and
shall not affect its meaning; 

  

	 	(l)	 references to documents “in the agreed form” are documents in the form agreed by or on behalf
of the Company and UM; 

  

	 	(m)	 references to a document are to that document as varied or novated (in each case, other than in breach of the
provisions of this Agreement) at any time; 

  

	 	(n)	 any phrase introduced by the terms “including”, “include”, in particular or
any similar expression shall be construed as illustrative and shall not limit the sense of the words introduced by those terms; 

  

	 	(o)	 references to “writing” and “written” include any non-transitory form of visible reproduction of words; 

  

	 	(p)	 references to “shall” and “will” are to be interpreted the same;

  

	 	(q)	 references in clause 1 (Definitions and Interpretation) (in so far as they are used in the clauses and
schedules referred to in this clause), clauses 7 (Warranties and Liability) and 10 (Confidentiality) and schedule 3 (Warranties) to the Company and the Board shall include each Group Company and the directors for the time being
of those Group Companies; 

  

	 	(r)	 “€” or “euros” denotes the lawful currency of certain members of the European Union,
including the Republic of Ireland; and 

  
 6 

	 	(s)	 “£” or “pounds sterling” denotes the lawful currency of Great Britain and Northern
Ireland. 

  

	2.	 CONTRIBUTION 

  

	2.1	 Subject to the terms of this Agreement, each Seller (in respect of itself only) shall sell, free from all
Encumbrances (save for those which arise pursuant to the Company’s Constitution) and with full title guarantee together with all rights and benefits (including voting rights, subscription rights and the right to receive dividends of the
Company) now or hereafter attaching thereto, the Sale Shares set out opposite such Seller’s name in column (4) of the table in Schedule 1 and UM shall purchase such Sale Shares with all rights attaching to them accordingly, in accordance
with clause 2.3 (the “Contribution”). Following the Contribution, the entire issued share capital of the Company will be owned by UM. 

  

	2.2	 Each Seller hereby waives any pre-emption rights or other restrictions
on transfer in respect of the Sale Shares, whether conferred by the Company’s Constitution, the Existing Agreements or otherwise and consents for all purposes to such transfer and all transactions contemplated by the Transaction Documents for
the purpose of the Existing Agreements, the Company’s Constitution and for all other purposes whatsoever. 

  

	2.3	 In consideration for each of the Sellers’ obligations in this clause 2, UM shall allot and issue the UM
Shares to the Sellers (credited as fully paid) in such number as set out opposite their respective names in column (5) of the table in Schedule 1. 

  

	2.4	 Each Seller (in respect of itself only) acknowledges and agrees that it is only entitled to the UM Shares set
out opposite its name in column (5) of the table in Schedule 1 in connection with the Contribution and no other shares in UM. The foregoing acknowledgement and agreement and the warranty at clause 6.1(i) are given by each Seller in reliance on
the accuracy of the warranty given by UM pursuant to clause 5.1(i). If the warranty given by UM pursuant to clause 5.1(i) is untrue or inaccurate, nothing in this clause 2.4 or clause 6.1(i) shall: (i) prevent a Seller from bringing a claim for
damages against UM in respect of such breach; (ii) reduce or otherwise affect UM’s liability in respect of such claim; and/or (iii) give rise to any liability on the part of the Sellers under this clause 2.4 or clause 6.1(i).

  

	2.5	 The UM Shares referred to in clause 2.3 shall be issued subject to, and having the rights set out in, UM’s
Constitution from time to time, including the right to receive all dividends, distributions or any return of capital declared, made or paid after the Completion Date with respect to such UM Shares. 

 

	2.6	 Each Seller, in respect of itself only, undertakes to UM that, if and for so long as such Seller remains the
registered holder of any of the Sale Shares after Completion, such Seller shall: 

  

	 	(a)	 hold such Sale Shares together with all dividend and any other distributions of profits or other assets in
respect of such Sale Shares, and all rights arising out of or in connection with them, on trust for UM; 

  

	 	(b)	 at all times after Completion, deal with and dispose of such Sale Shares, dividends, distributions, assets and
rights as UM shall direct and at all times in accordance with 

 UM’s Constitution; 

 

	 	(c)	 exercise all voting rights attached to such Sale Shares in such manner as UM shall direct (including by the
execution of any written shareholder resolution of the Company); and 

  

	 	(d)	 if required by UM, execute all instruments of proxy or other documents as may be necessary to enable UM to
attend and vote at any general meeting of the Company. 

  
 7 

	3.	 COMPLETION 

  

	3.1	 Subject to the satisfaction of the Condition, Completion shall take place by the release of electronic
signatures on the Completion Date (being such date and time determined by UM which shall be no later than the Business Day following the satisfaction of the Condition). 

 

	3.2	 For the avoidance of doubt, Completion shall occur simultaneously in respect of all Sale Shares and, for the
avoidance of doubt, shall not occur (and the Sellers shall not be required to transfer and UM shall not be required to complete the purchase of any Sale Shares) unless the entire issued share capital of the Company is transferred to UM.

  

	3.3	 Prior to or at Completion (as applicable) each Seller, the Company and UM shall comply with their respective
obligations as set out in Schedule 2. 

 3.4    If: 

 

	 	(a)	 any of the Sellers and/or the Company fail to comply with any obligation in Schedule 2, UM shall; or

  

	 	(b)	 UM fails to comply with any obligation in Schedule 2, a Sellers’ Majority shall, 

be entitled (in addition and without prejudice to all other rights and remedies available) by written notice on or before the date Completion
would otherwise be due to take place: 
  

	 	(i)	 to require Completion to take place so far as practicable having regard to the defaults which have occurred;

  

	 	(ii)	 to fix a new date for Completion (being not more than twenty (20) Business Days after the original date
for Completion) in which case the provisions of Schedule 2 shall apply to Completion as so deferred but on the basis that such deferral may only occur once; or 

 

	 	(iii)	 terminate this Agreement. 

 

	4.	 CONDITION 

4.1    Completion shall take place conditional on the Condition being satisfied. 

 

	4.2	 If the Condition is not fully satisfied by the Longstop Date, this Agreement shall automatically terminate with
immediate effect, except as provided by clause 4.3. 

  

	4.3	 If this Agreement terminates in accordance with clause 4.2, it shall immediately cease to have any further
force and effect except for: 

  

	 	(a)	 any provision of this Agreement that expressly or by implication is intended to come into or continue in force
on or after termination of this Agreement each of which shall remain in full force and effect (including clause 11 (Confidentiality) and clause 12 (Announcements)); and 

 

	 	(b)	 any rights, remedies, obligations or liabilities of the Parties that have accrued up to the date of
termination, including the right to claim damages in respect of any breach of this Agreement which existed at or before the date of termination. 

  

	4.4	 The Sellers and UM shall each use their respective commercially best efforts to procure (to the extent it lies
within their respective powers to do so) that the Condition can be satisfied as soon as reasonably practicable and, in any event, by no later than the Longstop Date, including using commercially best efforts to: 

  
 8 

	 	(a)	 take, or cause to be taken, all necessary action, and do, or cause to be done, all things necessary under
Applicable Law to consummate and make effective the transactions contemplated by this Agreement; and 

  

	 	(b)	 obtain all authorisations, consents, orders and approvals of, and give all notices to and make all filings
with, all Governmental Authorities and other third parties that are necessary for the performance of its obligations under this Agreement and the consummation of the transactions contemplated by this Agreement. 

 

	4.5	 UM shall notify the Sellers promptly upon becoming aware that the Condition has been fulfilled (or the
Condition becoming incapable of being fulfilled). 

  

	5.	 UM WARRANTIES 

 

	5.1	 UM warrants to each Seller that each of the following warranties in this clause is true and accurate as at the
Completion Date: 

  

	 	(a)	 it is validly incorporated, in existence and duly registered under the laws of its jurisdiction of
incorporation and has full power to conduct its business as conducted at the Completion Date; 

  

	 	(b)	 it has the legal right and full power and authority to enter into and perform this Agreement and each other
Transaction Document; 

  

	 	(c)	 this Agreement and each other Transaction Document will, when executed, constitute valid and binding
obligations on it, in accordance with its terms; 

  

	 	(d)	 it has obtained all governmental, statutory, regulatory or other consents, licences, authorisations, waivers or
exemptions and it has taken all corporate actions, required by it to authorise it to enter into and to perform this Agreement and each other Transaction Document; 

 

	 	(e)	 there are no: 

  

	 	(i)	 judgments, orders, injunctions or decrees of any Governmental Authority outstanding or affecting it or any of
its respective Affiliates; 

  

	 	(ii)	 law suits, actions or proceedings pending or, to the knowledge of UM, threatened against it or any of its
respective Affiliates; or 

  

	 	(iii)	 investigations by any Governmental Authority which are pending or threatened against it or any of its
respective Affiliates, 

 and which, in any such case, will have a material adverse effect on the ability of it to
lawfully execute and deliver, or perform, its obligations under this Agreement or any of the documents referred to in it; 
  

	 	(f)	 the execution, delivery and performance by it of this Agreement and each other Transaction Document will not:

  

	 	(i)	 result in a breach of, or constitute a default under its Constitution; 

 

	 	(ii)	 result in a breach of, or constitute a default under, any agreement or arrangement to which it is a party or by
which it is bound; or 

  

	 	(iii)	 result in, or amount to, a violation, default or breach of any law, regulation, statute, order, judgment or
decree of any Governmental Authority in any relevant jurisdiction, 

 in each case, other than any such breaches or
defaults that individually or in the aggregate would not impair in any material respect the ability of UM to perform its obligations under this Agreement, or prevent or materially impede or materially delay the consummation of the transactions
contemplated hereunder; 

  
 9 

	 	(g)	 it is not, nor will the consummation of the transactions contemplated by the Transaction Documents cause it to
become, insolvent or bankrupt under any laws applicable to it, nor is it unable to pay its debts as they fall due, nor has any arrangement (whether by court proceedings or otherwise) been proposed under which its creditors (or any group of them)
could receive less than the amounts due to them nor are any proceedings in relation to any compromise or arrangement with creditors, any winding up, bankruptcy or other insolvency proceedings concerning it (or any of its assets or interests) are
current, pending or threatened; 

  

	 	(h)	 the UM Shares are new duly issued shares (not already existing treasury shares or shares held by third parties)
and free of all Encumbrances (save for those set out in the UM Articles (e.g. pre-emption rights on transfer and drag along rights requiring the holders of the UM Shares to transfer the UM Shares to a bona
fide purchaser or similar rights)) and each of the Sellers will following Completion receive full legal and beneficial title to the relevant UM Shares with all rights attaching thereto; and 

 

	 	(i)	 the Fully Diluted Share Capital of UM immediately following the consummation of the Financing is set out in the
capitalisation table in Schedule 4. 

  

	5.2	 For the avoidance of doubt, for the purposes of this clause 5, the Affiliates of UM shall be those persons that
are Affiliates of UM at the close of business on the Business Day prior to the Completion Date. 

  

	6.	 FUNDAMENTAL WARRANTIES 

6.1    Each Seller severally warrants (in respect of themselves only) to UM that each of the 

Fundamental Warranties is true and accurate as at the Completion Date: 

 

	 	(a)	 in respect of each Seller which is a body corporate, it is validly incorporated, in existence and duly
registered under the laws of its jurisdiction of incorporation and has full power to conduct its business as conducted at the Completion Date; 

  

	 	(b)	 it has the legal right and full power and authority to enter into and perform this Agreement and each other
Transaction Document to which it is party; 

  

	 	(c)	 this Agreement and each other Transaction Document will, when executed, constitute valid and binding
obligations on it, in accordance with its terms; 

  

	 	(d)	 it has obtained all governmental, statutory, regulatory or other consents, licences, authorisations, waivers or
exemptions and it has taken all corporate actions, required by it to authorise it to enter into and to perform this Agreement and each other Transaction Document; 

 

	 	(e)	 there are no: 

  

	 	(i)	 judgments, orders, injunctions or decrees of any Governmental Authority outstanding or affecting it or, in
respect of each Seller which is a body corporate, any of its respective Affiliates; 

  

	 	(ii)	 law suits, actions or proceedings pending or, to the knowledge of that Seller, threatened against it or in
respect of each Seller which is a body corporate, any of its respective Affiliates; or 

  
 10 

	 	(iii)	 investigations by any Governmental Authority which are pending or threatened against it or in respect of each
Seller which is a body corporate, any of its respective Affiliates, 

 and which, in any such case, will have a material
adverse effect on the ability of it to lawfully execute and deliver, or perform, its obligations under this Agreement or any of the documents referred to in it; 
  

	 	(f)	 the execution, delivery and performance by it of this Agreement and each other Transaction Document to which it
is party will not: 

  

	 	(i)	 result in a breach of, or constitute a default under its Constitution; 

 

	 	(ii)	 result in a breach of, or constitute a default under, any material agreement or arrangement to which it is a
party or by which it is bound; or 

  

	 	(iii)	 result in, or amount to, a violation, default or breach of any law, regulation, statute, order, judgment or
decree of any Governmental Authority in any relevant jurisdiction, 

 in each case, other than any such breaches or
defaults that individually or in the aggregate would not impair in any material respect the ability of the Seller to perform its obligations under this Agreement, or prevent or materially impede or materially delay the consummation of the
transactions contemplated hereunder; 
  

	 	(g)	 it is not, nor will the consummation of the transactions contemplated by the Transaction Documents cause it to
become, insolvent or bankrupt under any laws applicable to it, nor is it unable to pay its debts as they fall due, nor has any arrangement (whether by court proceedings or otherwise) been proposed under which its creditors (or any group of them)
could receive less than the amounts due to them nor are any proceedings in relation to any compromise or arrangement with creditors, any winding up, bankruptcy or other insolvency proceedings concerning it (or any of its assets or interests) are
current, pending or threatened; 

  

	 	(h)	 the Sale Shares set out opposite its name in column (4) of the table in Schedule 1: (i) comprise all of
the shares it owns in the Company; and (ii) have been properly and validly allotted and issued and are each fully paid up, and other than such Sale Shares, it does not own any other equity, debt or hybrid securities, including any debentures,
warrants, options, rights of conversion, exchange or subscription, or any other interests issued or issuable with respect to the foregoing which remain outstanding and unexercised as at the Completion Date; 

 

	 	(i)	 it is only entitled to the UM Shares set out opposite its name in column (5) of the table in Schedule 1 in
connection with the Contribution and no other Ordinary Shares; and 

  

	 	(j)	 other than the Sale Shares, the Company has not issued any other equity, debt or hybrid securities, including
any debentures, warrants, options, rights of conversion, exchange or subscription, or any other interests issued or issuable with respect to the foregoing which remain outstanding and unexercised as at the Completion Date. 

 

	7.	 WARRANTIES AND LIABILITY 

 

	7.1	 Each of the Warrantors severally warrants (in respect of themselves only) to UM that each of the Warranties
(other than the Fundamental Warranties) is true and accurate as at the date of this Agreement. Each of the Warranties (other than the Fundamental Warranties) shall be deemed to be made in respect of each Warrantor to the knowledge and belief of such
Warrantor, which knowledge and belief shall be interpreted to extend to those facts, matters and circumstances of which such Warrantor is actually aware as at the date of this Agreement having made reasonable enquiry of each other Warrantor and also
such knowledge which such Warrantor would have had if they had made reasonable enquiry of the Relevant Persons. 

  
 11 

	7.2	 Each Warranty is given subject to the matters Disclosed and any limitations, exceptions or exclusions expressly
provided for in this Agreement. 

  

	7.3	 Each of the Warranties shall be construed as separate and independent, and (unless expressly provided to the
contrary) shall not be limited by the terms of any other Warranties or by any other term of this Agreement or the Disclosure Letter. 

  

	7.4	 Without limitation to the rights of UM under this Agreement, in the case of a Claim against any Warrantor, no
counterclaim or right of contribution or indemnity shall lie against the Company and/or any of the other Sellers. 

  

	7.5	 The Warranties shall continue in full force and effect, notwithstanding Completion and the rights and remedies
of UM in respect of any breach of any of the Warranties or any of the Fundamental Warranties shall not be affected by Completion, any investigation made by or on behalf of UM into the affairs of the Company or any other event or matter whatsoever
which otherwise might have affected such rights and remedies except a specific and duly authorised written waiver or release. 

  

	7.6	 Any information supplied by the Company, its officers, employees or agents to the other Warrantors or their
agents, representatives or advisers in connection with, or which forms the basis of, any of the Warranties or any matter covered in the Disclosure Letter or otherwise in relation to the business and affairs of the Company (whether before or after
the date hereof) shall be deemed not to include or have included a representation, warranty or guarantee of its accuracy by the Company to the other Warrantors and shall not constitute a defence to any Claim by UM. The Warrantors hereby irrevocably
waive any and all claims against the Company, its officers, employees or agents in respect of any information so supplied. 

  

	7.7	 Each of the Warrantors hereby confirms that, save for the matters being Disclosed, the Warrantor is not
actually aware of any fact, matter and/or circumstance which would constitute a breach of any Warranty. For the purposes of this confirmation each Warrantor’s awareness shall be deemed to include those facts, matters and circumstances of which
such Warrantor is actually aware as at the date of this Agreement having made reasonable enquiry of each other Warrantor and also such knowledge which such Warrantor would have had if they had made reasonable enquiry of the Relevant Persons.

  

	8.	 LIMITATIONS ON CLAIMS 

 

	8.1	 The limitations set out in this Agreement (including this clause 8) shall not apply to any Relevant Claim which
is the consequence of fraud, dishonesty or deliberate concealment by or on behalf of a Warrantor, a Seller or UM (as applicable) in respect of any Warranties or Fundamental Warranties (as applicable). 

 

	8.2	 No Claim may be made against any Warrantor unless written notice of that Claim is served on any Warrantor
giving reasonable details of the Claim by no later than the date falling eighteen (18) months from the Completion Date. Failure to give reasonable details of any Claim shall not prevent UM from proceeding with any Claim otherwise made properly
under this Agreement. 

  

	8.3	 A Claim will be deemed to be withdrawn (if it has not been previously satisfied, settled or withdrawn and no
new Claim may be made in respect of the facts giving rise to such withdrawn Claim) unless proceedings in respect of that Claim have been issued before the date falling six 

(6)    months after the date on which such Claim is notified in accordance with clause 8.2. For these purposes, proceedings
in respect of a Claim will be deemed to have been “issued” on the date entered on the claim form issued by the court at the request of the relevant claimant. 
  

	8.4	 No Fundamental Warranty Claim may be made against any Seller (including, for the avoidance of doubt, any
Warrantor) or UM (as applicable) unless written notice of that Fundamental Warranty Claim is served on any Seller (including, for the avoidance of doubt, any Warrantor) or UM (as applicable) giving reasonable details of that Fundamental Warranty
Claim by no later than the date falling three (3) years from the Completion Date. Failure to give reasonable details of any Fundamental Warranty Claim shall not prevent UM or any Seller (as applicable) from proceeding with any Fundamental
Warranty Claim otherwise made properly under this Agreement. 

  
 12 

	8.5	 A Fundamental Warranty Claim will be deemed to be withdrawn (if it has not been previously satisfied, settled
or withdrawn and no new Fundamental Warranty Claim may be made in respect of the facts giving rise to such withdrawn Fundamental Warranty Claim) unless proceedings in respect of that Fundamental Warranty Claim have been issued before the date
falling twelve (12) months after the date on which such Fundamental Warranty Claim is notified in accordance with clause 8.4. For these purposes, proceedings in respect of a Fundamental Warranty Claim will be deemed to have been
“issued” on the date entered on the claim form issued by the court at the request of the relevant claimant. 

  

	8.6	 The maximum aggregate liability of the Warrantors in respect of all and any Claims shall be limited to, in the
case of the Company and each of the other Warrantors, £1.00. 

  

	8.7	 The maximum aggregate liability of each Seller in respect of all and any Fundamental Warranty Claims under this
Agreement shall be limited to the amount set opposite such Seller’s name in column (6) of Schedule 1. 

  

	8.8	 The maximum aggregate liability of UM in respect of all and any Fundamental Warranty Claims under this
Agreement shall be limited to the amount set out in the bottom row of column (6) of Schedule 1. 

  

	8.9	 UM shall be entitled to make a Relevant Claim in respect of liability which is contingent or unascertained
provided that (i) written notice of the Relevant Claim is given to any Warrantor or Seller (as applicable) in accordance with and before the expiry of the relevant period specified in clause 8.2 or 8.4 (as applicable) and (ii) no Warrantor
or Seller (as applicable) shall have any liability in respect of such Relevant Claim unless and until such contingent liability becomes an actual liability or the liability is capable of being ascertained. 

 

	8.10	 No Party nor any other member of its group shall be entitled to recover damages or obtain payment,
reimbursement, restitution or indemnity more than once in respect of any loss arising from any Relevant Claim, with the intent that there shall be no double recovery. 

 

	8.11	 No Party nor any other member of its group shall be entitled to make a Relevant Claim for any punitive or
special loss. 

  

	8.12	 Nothing in this Agreement shall prejudice any Party’s duty under common law to mitigate any loss or
liability which is the subject of a Relevant Claim. 

  

	9.	 TAX 

UM shall bear the cost of all UK stamp duty and stamp duty reserve tax payable as a result of the transactions contemplated by this Agreement.
UM shall arrange the payment of such stamp duty and stamp duty reserve tax. 
  

	10.	 CONFIDENTIALITY 

 

	10.1	 Each Seller shall (and shall procure, where relevant, that each other member of its group and their respective
officers, employees, agents and advisers shall) in all respects keep confidential and not at any time disclose or make known in any way to any Person or use for its own or any other Person’s benefit or to the detriment of another Party to this
Agreement: 

  

	 	(a)	 any Confidential Information; and 

 

	 	(b)	 the terms of this Agreement and each of the Transaction Documents. 

 

	10.2	 Provided that in respect of the obligations set out in clause 10.1: 

  
 13 

	 	(a)	 such obligation shall not apply to information which becomes publicly available (other than through a breach of
this clause 10); 

  

	 	(b)	 each Seller shall be entitled at all times to disclose such information as may be required by law, for the
purpose of any judicial or arbitral proceedings or by any competent judicial or regulatory authority (including any Tax Authority) or by any relevant investment or stock exchange to whose rules such Seller or any of its Affiliates is subject,
provided that such Seller shall consult with UM prior to such Party making any such disclosure under this clause 10.2(b); 

  

	 	(c)	 any Preference Seller shall be entitled to disclose the terms of this Agreement and each of the Transaction
Documents to their investment committees, direct and indirect shareholders and their current and prospective limited partners (including venture partners) and other current and future investors in their respective funds (conditional upon any such
Person being subject to an obligation to keep such information confidential on the same basis as the Preference Seller for as long as such Preference Seller is obliged to do so in accordance with this clause 10); 

 

	 	(d)	 each Seller shall be entitled to disclose to its officers, employees, agents or advisers (including auditors)
such information as may be necessary to enable them to carry out their duties (conditional upon any such Person being subject to an obligation to keep such information confidential on the same basis as such Seller for as long as such Seller is
obliged to do so in accordance with this clause 10); and 

  

	 	(e)	 each Seller may disclose or use information if and to the extent that such disclosure or use is to a Tax
Authority or is otherwise in connection with the Taxation affairs of the disclosing Seller. 

  

	10.3	 The restrictions contained in this clause 10 shall continue to apply after Completion until the date falling
ten (10) Business Days after the expiration of the relevant statute of limitation period. 

  

	11.	 ANNOUNCEMENTS 

 

	11.1	 Except in accordance with clause 11.2, the Company and the Sellers shall not make any public announcement or
issue a press release or respond to any enquiry from the press or other media concerning or relating to this Agreement or its subject matter (including but not limited to the Sellers’ investment in the Company) or any ancillary matter without
the prior written consent of the Board. 

 11.2    Notwithstanding clause 11.1, any Seller may: 

 

	 	(a)	 make any press release to the effect that it has made an investment in the Company and/or that it is a
shareholder in the Company without obtaining the prior approval of the Board; 

  

	 	(b)	 make or permit to be made an announcement concerning or relating to this Agreement or its subject matter or any
ancillary matter with the prior written approval of the Board or if and to the extent required by: 

  

	 	(i)	 applicable law; 

  

	 	(ii)	 any securities exchange on which such Seller’s securities are listed or traded; 

 

	 	(iii)	 any regulatory or governmental or other authority with relevant powers to which such Seller is subject or
submits, whether or not the requirement has the force of law; or 

  

	 	(iv)	 any court order. 

  
 14 

	12.	 FURTHER ASSURANCE 

 

	12.1	 The Parties shall at their own cost use all reasonable endeavours from time to time on or following Completion,
on being required to do so by any other Party, to do or procure the doing of all such acts and/or execute or procure the execution of all such documents in a form reasonably satisfactory to the other Party for giving full effect to this Agreement
and securing to the other Parties the full benefit of the rights, powers, privileges and remedies conferred upon any Party in this Agreement. 

  

	12.2	 Each of the Sellers and UM shall procure that their respective Affiliates comply with all obligations under
this Agreement which are expressed to apply to such Affiliates. 

  

	13.	 EFFECT OF COMPLETION 

The Warranties, the Fundamental Warranties and the warranties given by UM pursuant to clause 5 (and the remedies of any Party in respect of any
breach of the Warranties, the Fundamental Warranties, any warranties given by UM pursuant to clause 5 or for fraud, dishonesty or deliberate concealment) and all other provisions of this Agreement, to the extent that they have not been performed by
Completion, shall continue in force after and notwithstanding Completion and shall not be extinguished or affected by Completion or by any other event or matter except by a specific and duly authorised written waiver or release given under and in
accordance with clause 16. 
  

	14.	 COSTS 

  

	14.1	 The Parties shall bear their own costs and disbursements incurred in the negotiations leading up to and in the
preparation of this Agreement and of matters incidental to this Agreement. 

  

	15.	 CUMULATIVE REMEDIES 

The rights, powers, privileges and remedies conferred upon the Parties in this Agreement are cumulative and are not exclusive of any other
rights, powers, privileges or remedies provided by law. 
  

	16.	 WAIVER 

The express or implied waiver by any Party of any of its rights or remedies arising under this Agreement or by law shall not constitute a
continuing waiver of the right or remedy waived or a waiver of any other right or remedy. 
  

	17.	 ENTIRE AGREEMENT 

 

	17.1	 This Agreement (including all the Schedules thereto) and the other Transaction Documents supersede and
extinguish any prior drafts, agreements, undertakings, representations, warranties and arrangements of any nature whatsoever, whether or not in writing, between any or all of the Parties in relation to the subject matter of this Agreement, including
the proposal letter between UM and the Company dated 2 November 2020. 

  

	17.2	 Each of the Parties acknowledges and agrees that it has not entered into this Agreement and will not enter into
the Transaction Documents in reliance on any statement or representation of any Person (whether a Party or not) other than as expressly incorporated in this Agreement and/or any other Transaction Document. 

 

	17.3	 Without limiting the generality of the foregoing, each of the Parties irrevocably and unconditionally waives
any right or remedy it may have to claim damages and/or to rescind this Agreement by reason of any misrepresentation (other than a fraudulent misrepresentation) having been made to it by any Person (whether Party or not) and upon which it has relied
in entering into this Agreement. 

  
 15 

	17.4	 Each of the Parties acknowledges and agrees that the only cause of action available to it under the terms of
this Agreement and the documents referred to or incorporated in this Agreement in respect of a Claim or in respect of a Fundamental Warranty Claim against UM shall be for breach of contract. 

 

	17.5	 Save as set out in clause 17.4 above, each of the Parties acknowledges and agrees that damages alone may not be
an adequate remedy for the breach of any of the undertakings or obligations as set out in this Agreement. Accordingly, without prejudice to any other rights and remedies the Parties may have, the Parties shall be entitled to seek the remedies of
injunction, specific performance or other equitable relief for any threatened or actual breach of the terms of this Agreement. 

  

	17.6	 Nothing contained in this Agreement or in any other document referred to or incorporated in it shall be read or
construed as excluding any liability or remedy as a result of fraud, dishonesty or deliberate concealment. 

  

	18.	 VARIATION 

Any variation of this Agreement is valid only if it is in writing and signed by UM, the Company and a Sellers’ Majority. 

 

	19.	 NO PARTNERSHIP 

Nothing in this Agreement is intended to or shall be construed as establishing or implying any partnership of any kind between the Parties.

  

	20.	 ASSIGNMENT AND TRANSFER 

 

	20.1	 Except as permitted by this clause 20, unless explicitly agreed in writing by UM, neither the Company nor any
Seller shall assign, transfer, charge or otherwise deal with all or any of its rights under this Agreement nor grant, declare, create or dispose of any right or interest in it. 

 

	20.2	 UM may assign its rights and obligations under this Agreement to, and it may be enforced by, any Permitted
Assignee as if it were UM under this Agreement. Any Permitted Assignee to whom an assignment is made in accordance with the provisions of this clause 20.2 may itself make an assignment as if it were UM under this clause 20.2. For the purposes of
this clause 20.2, a “Permitted Assignee” means each and any of UM’s subsidiaries from time to time. 

  

	20.3	 Notwithstanding clause 20.2, no assignment by UM or a Permitted Assignee shall increase the liability of any
Seller to any Person by reference to the liability that any such Seller would otherwise have had had the relevant assignment not taken place. 

  

	21.	 RIGHTS OF THIRD PARTIES 

 

	21.1	 Subject to clause 21.2, this Agreement does not confer any rights on any person or party (other than the
Parties) pursuant to the Contracts (Rights of Third Parties) Act 1999. 

  

	21.2	 The general partner of a Seller or the management company authorised from time to time to act on behalf of that
Seller or another person or persons nominated by that Seller, shall be entitled to enforce all of the rights and benefits under this Agreement at all times as if a Party. 

 

	22.	 COUNTERPARTS; NO ORIGINALS 

This Agreement may be executed in any number of counterparts, each of which shall constitute an original, and all the counterparts shall
together constitute one and the same agreement. The exchange of a fully executed version of this Agreement (in counterparts or otherwise) by electronic transmission (including pdf or other digital format including any electronic signature complying
with the Electronic Signatures in Global and National Commerce Act 2000, e.g., www.docusign.com) or by facsimile and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes and
shall be sufficient to bind the Parties to the terms and conditions of this Agreement. No exchange of original signatures is necessary. 

  
 16 

	23.	 NOTICES 

  

	23.1	 To be valid, any communication and/or information to be given in connection with this Agreement must be in
writing in English and either be delivered by hand or sent by first class post, email or other electronic form: 

  

	 	(a)	 to any body corporate which is a Party at its registered office; or 

 

	 	(b)	 to any Seller the address of that Seller set out in column (2) of Schedule 1, 

or in each such case such other address as the recipient may notify to the other Parties for such purpose in accordance with this clause 23.

  

	23.2	 A communication sent according to clause 23.1 shall be deemed to have been received: 

 

	 	(a)	 if delivered by hand, at the time of delivery; 

 

	 	(b)	 if sent by pre-paid first class post, on the second day after posting;
or 

  

	 	(c)	 if sent by email or other electronic form, at the time of completion of transmission by the sender,

 except that if a communication is received between 17:30 on a Business Day and 09:30 on the next Business Day, it shall
be deemed to have been received at 09:30 on the second of such Business Days. 
  

	24.	 SEVERANCE 

  

	24.1	 If any provision of this Agreement is held to be invalid or unenforceable by any judicial or other competent
authority, all other provisions of this Agreement will remain in full force and effect and will not in any way be impaired. 

  

	24.2	 If any provision of this Agreement is held to be invalid or unenforceable but would be valid or enforceable if
some part of the provision were deleted, the provision in question will apply with the minimum modifications necessary to make it valid and enforceable. 

  

	25.	 GOVERNING LAW 

This Agreement (and any dispute or claim relating to it or its subject matter (including
non-contractual claims)) is governed by and is to be construed in accordance with English law. 
  

	26.	 JURISDICTION 

The Parties irrevocably agree that the courts of England and Wales shall have exclusive jurisdiction to settle any claim, dispute or issue
(including non-contractual claims) which may arise out of or in connection with this Agreement. 

[Intentionally left blank, the schedules and signature pages follow.] 

  
 17 

 SCHEDULE 1: SELLERS 

 

											
	 (1)

Seller
	  	 (2)

Address
	  	 (3)

Email Address
	  	 (4)

Sale Shares
	  	 (5)
Number of
UM Shares
	  	 (6)

Maximum
Aggregate
Liability (€)

	 [####]
 [####]
	  	 [####]
 [####]
	  	 [####]
	  	[####]	  	[####]	  	[####]
	[####]	  	 [####]
 [####]

[####]
	  	[####]	  	[####]	  	[####]	  	[####]
	 [####]
 [####]

[####]
	  	 [####]
 [####]

[####]
	  	 [####]
 [####]

[####]
	  	[####]	  	[####]	  	[####]
						
		  	 [####]
 [####]

[####]
 [####]

[####]
 [####]

[####]
 [####]

 
 [####]

[####]
	  		  	[####]	  	[####]	  	[####]
	 [####]
 [####]
	  	 [####]
 [####]

[####]
 [####]

[####]
	  	[####]	  	[####]	  	[####]	  	[####]
	 [####]
 [####]

[####]
	  	 [####]
 [####]

[####]
 [####]

[####]
	  	[####]	  	[####]	  	[####]	  	[####]
	 [####]
 [####]

[####]
	  	 [####]
 [####]

[####]
	  	 [####]
 [####]
	  	[####]	  	[####]	  	[####]

  
 18 

											
	 [####]
 [####]
	 	 [####]
 [####]
	 	 [####]
	  	[####]	  	[####]	  	[####]
	[####]	 	 [####]
 [####]

[####]
	 	[####]	  	[####]	  	[####]	  	[####]
	 [####]
 [####]

[####]
	 	 [####]
 [####]

[####]
	 	 [####]
 [####]

[####]
	  	[####]	  	[####]	  	[####]
						
		 	 [####]
 [####]

[####]
 [####]

[####]
 [####]

[####]
 [####]

 
 [####]

[####]
	 		  	[####]	  	[####]	  	[####]
	 [####]
 [####]
	 	 [####]
 [####]

[####]
 [####]

[####]
	 	[####]	  	[####]	  	[####]	  	[####]
	 [####]
 [####]

[####]
	 	 [####]
 [####]

[####]
 [####]

[####]
	 	[####]	  	[####]	  	[####]	  	[####]
	 [####]
 [####]

[####]
	 	 [####]
 [####]

[####]
	 	 [####]
 [####]
	  	[####]	  	[####]	  	[####]

  
 19 

 SCHEDULE 2: COMPLETION OBLIGATIONS 

 

	1.	 PRE-COMPLETION OBLIGATIONS  

At or prior to Completion: 
  

	 	(a)	 each of the Sellers shall deliver to UM: 

 

	 	(i)	 stock transfer forms in the agreed form in respect of the Sale Shares set out against its name in column
(4) of the table in Schedule 1, duly executed by such Seller in favour of UM; and 

  

	 	(ii)	 share certificate(s) in respect of the Sale Shares (or, if required, an indemnity for lost share certificate(s)
in a form reasonably acceptable to UM); 

  

	 	(b)	 the Sellers shall procure that each of the Resigning Directors shall deliver to UM the written resignations (in
the agreed form) as directors of the Company, in each case to take effect on the Completion Date; 

  

	 	(c)	 UM shall procure that each of the New Directors shall deliver to the Company a letter pursuant to which he
expresses his willingness to act as a director of the Company (in the agreed form); 

  

	 	(d)	 the Company Resolutions shall be passed by the Sellers; and 

 

	 	(e)	 the UM Resolutions shall be passed by the relevant members of UM. 

 

	2.	 AT COMPLETION 

 

	2.1	 At Completion: 

  

	 	(a)	 each Seller shall release their stock transfer form(s) and transfer the Sale Shares to UM;

  

	 	(b)	 a meeting of the board of directors of the Company shall be held and board minutes shall be approved and signed
by the chairman of the meeting (or written resolutions of the board of directors of the Company shall be entered into by each director) pursuant to which the Company shall: 

 

	 	(i)	 ratify the terms of the Company Resolutions and the New Articles and the circulation of these to the Sellers;

  

	 	(ii)	 ratify the terms of and entry into this Agreement; 

 

	 	(iii)	 approve the terms of and entry into each of the documents to be entered into by the Company which are referred
to herein as being in agreed form; 

  

	 	(iv)	 subject to receipt of the stock transfer forms in relation to the Sale Shares duly stamped and (where
appropriate) adjudicated: 

  

	 	(A)	 register the transfer of the Sale Shares from the Sellers to UM; 

 

	 	(B)	 cancel the share certificates held by the Sellers in respect of the Sale Shares; and 

 

	 	(C)	 execute and deliver share certificate(s) to UM for the Sale Shares; 

 

	 	(v)	 approve the resignation of the Resigning Directors as directors of the Company; 

  
 20 

	 	(i)	 approve the form of and entry into the Director Deed of Indemnity with each New Director;

  

	 	(vi)	 approve the appointment of the New Directors as directors of the Company; 

 

	 	(vii)	 amend the accounting reference date to 31 December; and 

 

	 	(viii)	 pass any such other resolutions as may be required to carry out the obligations of the Company under this
Agreement; 

  

	 	(c)	 a meeting of the Board shall be held and board minutes shall be approved and signed by the chairman of the
meeting (or written resolutions of the Board shall be entered into by each director) pursuant to which UM shall: 

  

	 	(i)	 ratify the terms of the UM Resolutions and the circulation of these to the shareholders of UM eligible to vote
on each; 

  

	 	(ii)	 ratify the terms of and entry into this Agreement and the Disclosure Letter; 

 

	 	(ix)	 approve the terms of and entry into this Agreement and each of the documents to be entered into by UM which are
referred to herein as being in the agreed form; 

  

	 	(iii)	 issue the UM Shares credited as fully paid to each of the Sellers in the numbers set out in column (5) of
the table in Schedule 1, and enter the name of each of such Sellers in the register of members (and, in the case of a Seller who is already a shareholder of UM, make an additional entry next to their name in the register of members);

  

	 	(iv)	 execute and deliver a share certificate to each of the relevant Sellers for the UM Shares set out against its
name in column (5) of the table in Schedule 1; and 

  

	 	(x)	 pass any such other resolutions as may be required to carry out the obligations of UM under this Agreement;

  

	 	(d)	 each Seller (other than each Preference Seller and Cambridge Enterprise Limited) shall enter into and deliver
to UM a Power of Attorney; 

  

	 	(e)	 each Seller shall enter into and deliver to UM a Voting Power of Attorney; 

 

	 	(f)	 each Seller and the Company shall sign and deliver to UM its signature to the Deed of Termination;

  

	 	(g)	 the Company shall sign and deliver a Director Deed of Indemnity to each New Director, and UM shall procure that
each New Director shall sign and deliver the same to the Company; 

  

	 	(h)	 UM shall deliver a notice to the Company confirming that it is a registrable relevant legal entity (within the
meaning of section 790C of the Act) in relation to the Company; 

  

	 	(i)	 UM shall file Companies House form SH01 (return of allotment of shares) in respect of the allotment of the UM
Shares pursuant to this Agreement; 

  

	 	(j)	 the Company shall make all filings with Companies House as made be required by the actions set out in this
Agreement; and 

  

	 	(k)	 all necessary tax filings and elections shall be made, including submitting stock transfer forms for stamping.

  
 21 

			
	SCHEDULE 3: WARRANTIES
	For the purposes of this Schedule:
		
	409A Plan	  	means a nonqualified deferred compensation plan (as such term is defined under Section 409A(d)(1) of the Code, as amended and the guidance thereunder) under which the Company or any of its Subsidiaries makes, is obligated to
make or promises to make, payments;
		
	Accounts	  	means the financial statements of the Company for the twelve (12) Month period ended on the Accounts Date in the agreed form, consisting of an unaudited balance sheet of the Company as at the Accounts Date and the notes
thereto;
		
	Accounts Date	  	means 30 June 2019;
		
	Code	  	means the Internal Revenue Code of 1986, as amended;
		
	Data Protection Legislation	  	means the Data Protection Act 2018, the General Data Protection Regulation 2016/679, the Privacy and Electronic Communications Directive 2002/58/EC (as amended), the Privacy and Electronic Communications (EC Directive) Regulations
2003 (as amended), the Regulation of Investigatory Powers Act 2000, the Telecommunications (Lawful Business Practice) (Interception of Communications) Regulations 2000 and all applicable laws and regulations relating to processing of personal data,
including where applicable the guidance and codes issued by the Information Commissioner or other appropriate supervisory authority;
		
	Data Protection Principles	  	has the same meaning as the term “Data Protection Principles” under the Data Protection Legislation;
		
	Disclosure Bundle	  	has the meaning set out in the Disclosure Letter;
		
	DPA	  	means the Defense Product Act of 1950, as amended;
		
	Employee	  	means an individual who is employed by, or who provides consultancy services to, the Company or any Group Company;
		
	FDA	  	means the U.S. Food and Drug Administration;
		
	FDA Application Integrity Policy	  	means the FDA’s “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities” policy as stated at 56 Fed. Reg. 46191 (September 10, 1991);
		
	Grant Funding	  	means any funding or other aid or assistance from any central, state or local government body or authority, any statutory undertaking, any other public body or authority, or any other body funded by public money;
		
	Information Commissioner	  	has the meaning set out in the Data Protection Legislation;
		
	Intellectual Property	  	means all patents, patent applications, trademarks, trademark applications, service marks, service mark applications, tradenames, copyrights, trade secrets, domain names, mask works, information and proprietary rights and processes,
similar

  
 22 

			
		  	or other intellectual property rights, subject matter of any of the foregoing, tangible embodiments of any of the foregoing, and licenses in to and under any of the foregoing, all rights of whatsoever nature in computer software and
data, all rights of privacy and all intangible rights and privileges of a nature similar or allied to any of the foregoing, in every case in any part of the world and whether or not registered; and including all granted registrations and all
applications for registration in respect of any of the same;
		
	ITEPA	  	means the Income Tax (Earnings and Pensions) Act 2003;
		
	Management Accounts	  	means the management accounts of the Company for the period starting on Accounts Date and ending on the Management Accounts Date, in the agreed form;
		
	Management Accounts Date	  	means 30 November 2020;
		
	Personal Data	  	has the same meaning as the term “personal data” under the Data Protection Legislation;
		
	Properties	  	means, in respect of the Company or a Subsidiary, the properties set out in the Disclosure Letter;
		
	Securities Act	  	means the United States Securities Act of 1933, as amended;
		
	Social Obligations	  	means:
		
		  	 (a)   any common or statutory law, regulation, directive, code of practice or
other law in any jurisdiction relating to (i) the relationship between any Group Company and its employees (and/or Workers), any potential employee (and/or Worker) and/or any trade unions and/or (ii) the health and safety of its employees;
and
  
 (b)   any agreements or
arrangements between any Group Company and its employees and/or any trade union or other organisation which represents some or all of its employees;

		
	Tax Return	  	means any report, return (including information return), claim for refund, election, estimated tax filing, statement or declaration filed or required to be filed with a Tax Authority, including any schedule or attachment thereto,
and including any amendments thereof;
		
	VAT	  	means value added tax chargeable under the VATA or under any legislation replacing it or under any legislation which the VATA replaced and further means value added tax at the rate in force when the relevant supply is made and any
tax of a similar nature which is introduced in substitution for such value added tax;
		
	VATA	  	means the Value Added Tax Act 1994; and
		
	Workers	  	has the meaning set out in Chapter 8, section 88(3) of the Pensions Act 2008.

  

	1.	 Share capital and authority 

  
 23 

	1.1	 All of the shares set out in column 4 of the table in Schedule 1 are fully paid and comprise the entire issued
share capital of the Company. None of the share capital of the Company is under option or subject to any Encumbrance or other third party right (including rights of pre-emption), no options, warrants or other
rights to subscribe for new shares in the Company have been granted or agreed to, and no dividends or other rights or benefits have been declared, made or paid or agreed to be declared, made or paid thereon. All issued share capital of the Company
has been duly authorised and issued in compliance with applicable securities law. 

  

	1.2	 [Intentionally left blank.] 

 

	1.3	 The execution and delivery by the Company of this Agreement and the documents referred to in it, and
performance of its obligations and compliance with their respective terms, does not breach, conflict with or constitute a default under (with or without notice or lapse of time, or both), or give rise to a right of notice or termination,
cancellation, modification or acceleration of any right or obligation or loss of any benefit under, or require any consent, approval or waiver from any Person pursuant to, or result in the creation of any Encumbrance on the Company’s assets
pursuant to, the Company’s articles of association, or any other agreement or instrument to which any Warrantor is a party or by which any Warrantor is bound, and shall not constitute a breach under any order, judgment, decree or other
restriction applicable to any Warrantor. The Disclosure Letter sets out and describes all necessary consents, waivers and approvals of parties to any contracts to which the Company is a party or by which the Company’s properties or assets may
be bound as are required thereunder in connection with the transactions contemplated hereby, or for any such contract to remain in full force and effect without limitation, modification or alteration after Completion so as to preserve all rights of,
and benefits to, the Company under such contracts from and after Completion. Except as set out and described in the Disclosure Letter, following Completion, the Company will continue to be permitted to exercise all of its rights under all contracts
to which the Company is a party without the payment of any additional amounts or consideration other than ongoing fees, royalties or payments which they would otherwise be required to pay pursuant to the terms of such contracts had the transactions
contemplated hereunder not occurred. No consent, approval, order or authorisation of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority is required on the part of the Company
in connection with the consummation of the transactions contemplated by this Agreement, except for (i) the filing of the New Articles, which will have been filed as of Completion, and (ii) filings pursuant to applicable securities laws,
which have been made or will be made in a timely manner. 

 1.4 [Intentionally left blank.] 

 

	1.5	 Except as set forth in the New Articles, the Company has no obligation (contingent or otherwise) to purchase or
redeem any of its share capital. 

  

	1.6	 The Company believes in good faith that any 409A Plan complies in all material respects, in both form and
operation, with the requirements of Section 409A of the Code and the guidance thereunder. To the knowledge of the Company, no payment to be made under any 409A Plan is, or will be, subject to the penalties of Section 409A(a)(1) of the
Code. 

  

	1.7	 All action required to be taken by the board of directors of the Company and/or Sellers necessary for the
execution and delivery of this Agreement and the performance of all obligations of the Company under this Agreement has been taken. This Agreement, when executed and delivered by the Company, shall constitute valid and legally binding obligations of
the Company, enforceable against the Company in accordance with their respective terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating
to or affecting the enforcement of creditors’ rights generally or (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies. 

 

	1.8	 Except as provided in the Existing Agreements, the Company is not under any obligation to register under the
Securities Act any of its currently outstanding securities or any securities issuable upon exercise or conversion of its currently outstanding securities. To the Company’s knowledge, except as contemplated in the Existing Agreements, no
shareholder of the Company has entered into any agreements with respect to the voting of capital shares of the Company. 

  
 24 

	2.	 Information 

  

	2.1	 The information contained or referred to in columns (1) – (4) of Schedule 1 shall be true, complete and
accurate and not misleading immediately before Completion and the information contained or referred to in Schedule 5 shall be true, complete and accurate and not misleading immediately following Completion. 

 

	3.	 Business Plan 

 

	3.1	 The Business Plan has been diligently prepared and each of the Warrantors, believes that, as at the date of
this Agreement, it represents a realistic plan in relation to the future progress, expansion and development of the Business. 

  

	3.2	 All factual information contained in the Business Plan was when given and is at the date of this agreement
true, complete and accurate in all material respects and not misleading. 

  

	3.3	 The financial forecasts, projections or estimates contained in the Business Plan have been diligently prepared,
are fair, valid and reasonable nor have they been disproved in the light of any events or circumstances which have arisen subsequent to the preparation of the Business Plan up to the date of this Agreement. 

 

	3.4	 The assumptions upon which the Business Plan has been prepared have been carefully considered and are honestly
believed to be reasonable, having regard to the information available and to the market conditions prevailing at the time of their preparation. 

  

	3.5	 Each statement of opinion in the Business Plan is believed by each of the Warrantors to be fair and reasonable,
accurately to represent the opinion held by him and not to be misleading. 

  

	3.6	 So far as the Warrantors are aware, all matters within management control which could materially and adversely
affect the achievement of the financial forecasts in the Business Plan (other than general economic factors) are referred to in the Business Plan and have been taken into account in the preparation of such forecasts. 

 

	4.	 Accounts 

  

	4.1	 The Accounts have been prepared in accordance with accounting principles, standards and practices which are
generally accepted in the applicable jurisdiction in which such Accounts were prepared and on the same basis and in accordance with the same accounting policies as the corresponding accounts for the preceding three financial years, comply with the
requirements of applicable law and give a true and fair view of the state of affairs of the Company at the Accounts Date and of the profits and losses for the period concerned. UM has been provided with a complete copy of the Accounts.

  

	4.2	 The Accounts make proper provision or reserve for or, in the case of actual liabilities, properly disclose,
note or take into account as at the Accounts Date: 

  

	 	(a)	 all liabilities whether actual contingent or disputed; 

 

	 	(b)	 all capital commitments whether actual or contingent; 

 

	 	(c)	 all bad and doubtful debts; and 

 

	 	(d)	 all Taxation. 

  
 25 

	4.3	 The profits (or losses) shown in the Accounts have not to a material extent been affected (except as disclosed
therein) by any extraordinary or exceptional event or circumstance or by any other factor rendering such profits unusually high or low. 

  

	5.	 Management Accounts 

 

	5.1	 The Management Accounts: 

 

	 	(a)	 have been prepared in accordance with good accounting practice on a basis consistent with that upon which the
management accounts of the Company for the period to the Accounts Date were prepared; 

  

	 	(b)	 reasonably reflect the financial affairs of the Company at the date to which they have been prepared and its
results for the period covered by the Management Accounts; and 

  

	 	(c)	 are not inaccurate or misleading in any material respect. 

 

	5.2	 UM has been provided with a complete copy of the Management Accounts. 

 

	6.	 Events since the Accounts Date 

Since the Accounts Date, except in connection with or pursuant to the transactions contemplated by this Agreement (including the
Contributions): 
  

	 	(a)	 its business has been carried on in the ordinary course and so as to maintain the same as a going concern;

  

	 	(b)	 it has not acquired or disposed of or agreed to acquire or dispose of any business or any material asset (other
than trading stock in the ordinary course of the business carried on by it) or assumed or acquired any material liability (including a contingent liability); 

  

	 	(c)	 no dividend or other distribution has been declared, made or paid to its members nor has it repaid any loan
capital or other debenture; 

  

	 	(d)	 no change has been made (or agreed to be made) in the emoluments or other terms of employment of any of its
employees who are in receipt of remuneration in excess of £100,000 per annum or of any of the directors of the Company nor has it paid any bonus or special remuneration to any such employee or any of its directors; 

 

	 	(e)	 it has not borrowed monies (except in the ordinary course of the business carried on by it or from its bankers
under agreed loan facilities); 

  

	 	(f)	 there has not been any material deterioration in the financial position or prospects of the Business (whether
in consequence of normal trading or otherwise); 

  

	 	(g)	 neither the trading nor the profitability of the Business shows, as regards turnover, the state of order book,
expenses and profit margins, any material deterioration or downturn by comparison with the period ended on the Accounts Date; 

  

	 	(h)	 no part of the Business has been affected to a material extent by the loss of any important customer, or of any
source of supply or by the cancellation or loss of any order or contract or by any other abnormal factor or event nor so far as the Warrantors are aware are there any circumstances likely to lead thereto; 

 

	 	(i)	 no employee has been dismissed or made redundant nor has the Company taken or omitted to take any action which
would entitle any employee to claim that he has been constructively dismissed; 

  
 26 

	 	(j)	 no resignation or termination of employment of any officer or key employee of the Company;

  

	 	(k)	 no material change to a material contract or agreement by which the Company or any of its assets is bound or
subject; and 

  

	 	(l)	 there are no liabilities (including contingent liabilities) outstanding on the part of the Company other than
those liabilities disclosed in the Accounts or incurred in the ordinary and proper course of business since the Account Date which are similarly disclosed in the Management Accounts or in the books and records of the Company. 

 

	7.	 Taxation 

  

	7.1	 The Company has duly and punctually made all Tax Returns and given or delivered all notices, accounts and
information which ought to have been made to and is not and has not been involved in any dispute with any Tax Authority concerning any matter likely to affect in any way the liability (whether accrued, contingent or future) of it for Taxation and
the Warrantors are not aware of any matter which may lead to such dispute. 

  

	7.2	 The Company has duly paid or fully provided for all Taxation (including deferred tax) for which it is liable
and there are no circumstances in which interest or penalties in respect of Taxation not duly paid could be charged against it in respect of any period prior to Completion. 

 

	7.3	 All Taxation due in respect of payments made by the Company to any person, which ought to have been made under
deduction or reduction of Taxation, has been properly deducted and accounted for to the appropriate Tax Authority from all such payments made. 

  

	7.4	 All documents to which the Company is a party or which form part of the Company’s title to any asset owned
or possessed by it or which the Company may need to enforce or produce in evidence in the courts of the United Kingdom have been duly stamped and (where appropriate) adjudicated. 

 

	7.5	 No claim has been received by the Company from a jurisdiction in which Tax Returns have not been filed by the
Company that the Company is or may be subject to Taxation by such jurisdiction. 

  

	7.6	 The Company has not agreed to any waiver of any statute of limitations in respect of Taxation or has agreed to,
or is subject to, any extension of time with respect to a Taxation assessment or deficiency. 

  

	7.7	 The Company has not ever been a member of an affiliated, consolidated, combined, unitary or aggregate group or
filed any Tax Return as a member of such group (other than with respect to the combined, consolidated, affiliated or unitary group for Taxation purposes for which the Company is the common parent). 

 

	7.8	 The Company does not have any liability for Taxation of any other Person (i) as a result of having been a
member of an affiliated, consolidated, combined, unitary or aggregate group, (ii) under any Taxation sharing, allocation, indemnification or similar agreement or (iii) as a transferee or successor or as a result of contractual obligations.

  

	7.9	 The Company has complied in all material respects with applicable transfer pricing laws, has prepared all
necessary transfer pricing documentation as required by Applicable Law and filed all applicable Tax Returns with respect thereto. 

  

	7.10	 The taxable year of the Company is, and always has been, the calendar year ending 31 December. The Company and
each of its Subsidiaries is, and always has been, an accrual method taxpayer. 

  

	7.11	 The Company is not the beneficiary of any Taxation exemption, Taxation holiday or other Taxation reduction
agreement or order. 

  
 27 

	7.12	 The Company has never requested or received a ruling from any Tax Authority or signed a closing or other
agreement with any Tax Authority. 

  

	7.13	 The Company does not have and has never had any interest in any partnership, limited liability company or other
arrangement classified as a partnership for income tax purposes. 

  

	7.14	 No directors, officers or employees of the Company have received any securities, interests in securities or
securities options as defined in Part 7 of ITEPA. 

  

	7.15	 No directors, employees or officers of the Company have received any securities or interests in securities in a
form which is or could be treated as a “readily convertible asset” as defined in section 702 of ITEPA. 

  

	7.16	 All directors, officers or employees of the Company who have received any securities or interests in securities
falling within Chapter 2 of Part 7 of ITEPA have entered into elections jointly with the Company under section 431(1) of ITEPA within the statutory time limit and a list of any such directors, officers or employees and the elections entered into is
included in the Disclosure Bundle. To the Company’s knowledge, all elections and notices under Section 83(b) of the Code have been or will be timely filed by all individuals who have acquired Ordinary Shares that are or were subject to
vesting upon the grant thereof by the Company. 

  

	7.17	 The Company is a close company as defined in section 439 of the CTA 2010 and is not and has never been a close
investment-holding company as defined in section 34 of the CTA 2010. 

  

	7.18	 No distribution within section 1064 of the CTA 2010 has been made by the Company and no loan or advance within
sections 455, 459 and 460 of the CTA 2010 has been made (and remains outstanding) or agreed to, by the Company, and the Company has not, since the Accounts Date, released or written off the whole or part of the debt in respect of any such loan or
advance. 

  

	7.19	 All acquisitions or disposals of assets by the Company and all supplies of services by and to the Company have
occurred at arm’s length between unconnected persons and for a consideration in cash at market value. 

  

	7.20	 The Company is registered for the purposes of the VATA (and has not at any time been treated as a member of a
group of companies for such purpose). The Company has complied with all statutory provisions, regulations and notices relating to VAT and has duly and punctually accounted for and/or paid HMRC all amounts of VAT which it ought to have so accounted
for and/or paid. 

  

	7.21	 The Company is and since the time of its formation has been a corporation for United States federal income tax
purposes. 

  

	7.22	 Neither the Company nor any of its Subsidiaries has deferred or delayed any payment of Taxation or received any
tax credit under measures relating to COVID-19. 

  

	8.	 Litigation 

  

	8.1	 Neither the Company nor, so far as the Warrantors are aware, any person for whose acts and defaults it may be
vicariously liable, is at present engaged whether as claimant, defendant or otherwise in any legal action, proceeding or arbitration which is either in progress or is threatened or, so far as the Warrantors are aware, is pending (other than as
claimant in the collection of debts arising in the ordinary course of the business carried on by it none of which exceeds £100,000 and which do not exceed £250,000 in aggregate) or is being prosecuted for any criminal offence and no
governmental, regulatory or official investigation or inquiry concerning the Company is threatened or in progress or so far as the Warrantors are aware pending. 

 

	8.2	 There is no legal action, proceeding or arbitration currently threatened, so far as the Warrantors are aware,
that questions the validity of this Agreement or that would reasonably be expected to have, either individually or in the aggregate, a material adverse change in the financial or trading position of the Company. 

  
 28 

	8.3	 There is no action, suit, proceeding or investigation by the Company pending or which the Company intends to
initiate. 

  

	8.4	 There are no circumstances known to any of the Warrantors likely to lead to any such claim or legal action,
proceeding or arbitration, prosecution, investigation or inquiry. 

  

	8.5	 Neither the Company nor any of the Key Persons nor, so far as the Warrantors are aware, any person acting for
or on behalf of the Company is being prosecuted for an offence, nor are they or have they been the subject of any investigation, or inquiry by, or on behalf of, any governmental, administrative or regulatory authority, in respect of any offence or
alleged offence, under the Bribery Act 2010 or under applicable anti-corruption laws or regulations of any other jurisdiction, and there are no circumstances known to any of the Warrantors likely to give rise to any such prosecution, investigation
or inquiry. 

  

	9.	 Properties 

  

	9.1	 The Properties (and the interest held by the Company) are identified in the Disclosure Letter and they are the
only properties in which the Company has an interest or occupies. 

  

	9.2	 The details of the Properties are entirely accurate and incorporate all adverse rights (including, without
limitation, charges, leases, contracts, title and planning restrictions and Encumbrances) affecting the Properties. 

  

	9.3	 The Company has duly complied with the obligations affecting the Properties and no termination notice has been
given (by the landlord or the tenant) in relation to any lease relating to any of the Properties. 

  

	9.4	 There are no outstanding liabilities (actual, anticipated or contingent) in relation to any of the Properties
(including, without limitation, outstanding rent reviews and future duties to reinstate alterations) or in relation to any property formerly owned or occupied by the Company. 

 

	9.5	 The Properties are fully insured and the Company has appropriate rights to ensure any damage by an insured risk
is reinstated. 

  

	10.	 Intellectual Property 

 

	10.1	 The Company has taken reasonable and appropriate steps to protect all Intellectual Property and know-how used by it and the Company has not itself granted any rights to third parties in relation to any of its Intellectual Property. 

 

	10.2	 So far as the Warrantors are aware, neither (i) the use, commercialisation or development of any product
as presently contemplated by the Company, nor (ii) the manufacture of any product as presently manufactured or presently contemplated to be manufactured by or on behalf of the Company infringes any Intellectual Property right of any third party
and the Warrantors are not aware of any claims or applications for registration of Intellectual Property which might be material for disclosure to UM as the acquirer of the Company. 

 

	10.3	 All Intellectual Property, which is or is likely to be material to the business of the Company:

  

	 	(a)	 is (or in the case of applications will be) legally and beneficially vested exclusively in the Company; or

  

	 	(b)	 is licensed to the Company by third parties by way of an agreement and/or licence which enable the Company to
use the Intellectual Property as it requires in the ordinary course of its business. 

  
 29 

	10.4	 Details of all licences (true, current and complete copies of each of which are included in the Disclosure
Bundle) entered into by the Company in relation to Intellectual Property, and in respect of which the Company is a licensor, licensee or otherwise a party, are set out in the Disclosure Letter. 

 

	10.5	 No Intellectual Property in which the Company has any interest and which is, or is likely to be, material to
the business of the Company is: 

  

	 	(a)	 being (or has been) infringed, misappropriated or used without permission by any other person; or

  

	 	(b)	 subject to any licence, estoppel or authority or similar right in favour of any other person, except as set out
in the agreements listed in the Disclosure Letter. 

  

	10.6	 All Intellectual Property which is registered in the name of the Company, or in respect of which the Company
has made application for registration, is: 

  

	 	(a)	 listed and briefly described in the Disclosure Letter; 

 

	 	(b)	 legally and beneficially vested in the Company; and 

 

	 	(c)	 valid and enforceable and not subject to any claims of opposition from any third party. 

 

	10.7	 All renewal fees in respect of the Intellectual Property registered by the Company have been duly paid, and all
other steps required for the maintenance and protection of such registered Intellectual Property have been taken, in any jurisdiction in which they are registered. 

 

	10.8	 Nothing has been done or omitted to be done whereby any of the Intellectual Property owned or used by the
Company have ceased or might cease to be valid and enforceable or whereby any person is or will be able to seek cancellation, rectification or any other modification of any registration of any such Intellectual Property. 

 

	10.9	 No other person has registered or applied to register in any country any invention, topography, copyright work,
design, trade or service mark or name, trade secret or know-how or other Intellectual Property made, or claimed to be owned, by the Company. 

 

	10.10	 All licences, agreements and arrangements entered into by the Company in respect of which the Company is a
licensor, a licensee or otherwise a party have been entered into in the ordinary course of business, are in full force and effect and no notice has been given on either side to terminate any of them and no amendment made or accepted to their terms
since they were first entered into; and, so far as the Warrantors are aware, the obligations of all parties under each of the same have been fully complied with and no disputes exist or are anticipated in respect of any of them.

  

	10.11	 The Company has not knowingly disclosed or permitted to be disclosed to any person (other than to UM and to its
agents, employees or professional advisers) any of its know-how, trade secrets, confidential information or lists of customers or suppliers other than where the recipient is subject to an obligation owed to
the Company to keep any such information confidential pursuant to a confidentiality agreement or similar. 

  

	10.12	 Each employee has assigned to the Company all intellectual property rights he or she owns that are related to
the Company’s business as now conducted and as presently proposed to be conducted and all intellectual property rights that he, she or it solely or jointly conceived, reduced to practice, developed or made during the period of his, her or its
employment or consulting relationship with the Company that (i) relate, at the time of conception, reduction to practice, development, or making of such intellectual property right, to the Company’s business as then conducted or as then
proposed to be conducted, (ii) were developed on any amount of the Company’s time or with the use of any of the Company’s equipment, supplies, facilities or information or (iii) resulted from the performance of services for the
Company. To the Company’s knowledge, it will not be necessary to use any inventions of any of its employees (or Persons it currently intends to hire) made prior to their employment by the Company, including prior employees or consultants, or
academic or medical institutions with which any of them may be affiliated now or may have been affiliated in the past. 

  
 30 

	10.13	 Other than with respect to commercially available software products under standard end-user object code license agreements, there are no outstanding options, licenses, agreements, claims, encumbrances or shared ownership interests of any kind relating to the Company’s Intellectual Property to
which the Company is party, nor is the Company bound by or a party to any options, licenses or agreements of any kind with respect to the patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information, proprietary
rights and processes of any other Person. 

  

	10.14	 No government funding, facilities of a university, college, other educational institution or research center,
or funding from third parties was used in the development of any of the Company’s Intellectual Property. No Person who was involved in, or who contributed to, the creation or development of any of the Company’s Intellectual Property, has
performed services for the government, university, college, or other educational institution or research center in a manner that would affect the Company’s rights in its Intellectual Property. 

 

	11.	 Assets, debts and stock 

 

	11.1	 None of the book debts included in the Accounts, the Management Accounts or which have subsequently arisen have
been outstanding for more than two months from their due dates for payment and all such debts have realised or will realise in the normal course of collection their full value save as provided in the Accounts, the Management Accounts or in the books
of the Company. 

  

	11.2	 The Company has not granted any security over any part of its undertaking or assets. 

 

	11.3	 All assets used by and all debts due to the Company or which have otherwise been represented as being its
property or due to it or used or held for the purposes of its business are at the date of Completion its absolute property and none is the subject of any Encumbrance (save in respect of liens arising in the normal course of trading) or the subject
of any factoring arrangement, hire-purchase, retention of title, conditional sale or credit sale agreement. 

  

	12.	 Contracts with connected persons 

 

	12.1	 There are no loans made by the Company to any of its directors, officers, employees or shareholders and/or any
person connected with any of them and no debts or liabilities owing by the Company to any of its directors, officers, employees or shareholders and/or any person connected with them as aforesaid other than in connection with expenses or advances of
expenses incurred in the ordinary course of business or employee relocation expenses and for other customary employee benefits made generally available to all employees. 

 

	12.2	 There are no existing contracts or arrangements to which the Company is a party and in which any of its
directors, officers, employees or shareholders and/or any person connected with any of them is interested. 

  

	12.3	 None of the Company’s directors, officers, employees or employees or shareholders and/or any person
connected with any of them have any direct or indirect ownership interest in any firm or corporation with which the Company is connected or with which the Company has a business relationship, or any firm or corporation which competes with the
Company except that directors, officers, employees or shareholders of the Company may own stock in (but not exceeding two percent (2%) of the outstanding share capital of) publicly traded companies that may compete with the Company.

  

	12.4	 There are no agreements between any of the Key Persons and/or Sellers (in relation to the Company) or between
any of the Key Persons and/or Sellers and the Company other than this Agreement and the Existing Agreements. 

  
 31 

	12.5	 No Key Person nor any person connected with a Key Person owns any property used by the Company.

  

	13.	 Employment and consultancy arrangements 

 

	13.1	 Full details of all contracts of service or for services and other arrangements (including, without limitation,
compensation, length of service, details of notice periods, confidentiality obligations, intellectual property rights and obligations and all remuneration) of all officers, employees, workers and consultants of the Company (such contracts, the
“Employment Agreements”) are included in the Disclosure Letter. 

  

	13.2	 There are no agreements or other arrangements (binding or otherwise) or outstanding or anticipated claims or
disputes between the Company and any trade union or other body representing all or any of the employees of the Company. 

  

	13.3	 The Company does not owe any amount to, nor does it have any outstanding obligations in respect of, any of its
present or former directors, employees or shareholders other than remuneration accrued during the month in which this Agreement has been entered into. 

  

	13.4	 Save as Disclosed, there is not in existence nor is it proposed to introduce any share incentive, share option,
profit sharing, bonus or other incentive arrangements (the “Incentive Plans”) for or affecting any employees, consultants or former employees or former consultants. 

 

	13.5	 No gratuitous payment has been made or promised in connection with the actual or proposed termination or
suspension of employment or variation of any contract of employment or of any contract for services of any present or former director, employee, worker or consultant of the Company. 

 

	13.6	 No person has been or is employed by the Company who did not or does not have leave to enter or remain in the
United Kingdom or otherwise in breach of section 8 of the Asylum and Immigration Act 1996 or sections 15 to 21 (inclusive) of the Immigration, Asylum and Nationality Act 2006 (as applicable). 

 

	13.7	 There are no agreements or arrangements (whether legally enforceable or not), employee benefit plans within the
meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended, deferred compensation arrangements, change in control plans, vacation plans, employee benefit plans (the “Benefit Plans” and, collectively
with the Employment Agreements and the Incentive Plans, the “Employee Plans”) in relation to which the Company has incurred, will incur or could incur any liability or responsibility for or in relation to the provision of any
pensions, allowances, lump sums gratuities or other like benefits on redundancy, retirement, withdrawal from service or on death or during periods of sickness or disablement or accident for or in respect of any director, or former director or
employee or former employee of the Company or any person who has at any time agreed to provide services to the Company or any dependants of any such persons and no proposals or announcements have been made about the introduction, continuance,
variation of, or payment of any contribution towards any such agreements or arrangements. 

  

	13.8	 There is no outstanding dispute or complaint in relation to the types of benefits described in warranty
statement 13.7 and there have been no communications with the Pensions Advisory Service, the Pensions Ombudsman, HMRC, and/or the Pensions Regulator in relation to such benefits. 

 

	13.9	 Neither the Company nor any person who is an “associate” of or “connected” with it (as such
terms apply in sections 38 to 51 of the Pensions Act 2004) has, at any time since 19 December 1996, contributed towards, participated in or had employees who participated in, an occupational pension scheme to which section 75 of the Pensions
Act 1995 applies, has applied or can apply. 

  
 32 

	13.10	 No current or former employee or director of the Company has at any time since 30 August 1993 had his
contract of employment transferred during the present period of continuous employment as a result of a “relevant transfer” for the purposes of either the Transfer of Undertakings (Protection of Employment) Regulations 1981 (before those
regulations were revoked) or the Transfer of Undertakings (Protection of Employment) Regulations 2006 where he had previously been a member of an occupational pension scheme that provided benefits available other than on old age, invalidity or
death. 

  

	13.11	 Each current and former employee, consultant and officer of the Company has executed an agreement with the
Company providing for customary confidentiality and proprietary information obligations or such provisions are otherwise included in their employment agreement with the Company(the “Confidential Information Agreements”). No current
or former Key Person has excluded works or inventions from his or her assignment of inventions pursuant to such Key Person’s Confidential Information Agreement. Each current and former Key Person is bound by restrictive covenants in a form
which provides suitable protection to the Company against competition and solicitation. The Warrantors are not aware that any Key Person or former Key Person is in violation of any agreement described in this paragraph 13.11. 

 

	13.12	 True, complete and correct copies of the Employee Plans and, with respect to the Benefit Plans, the following
documents, where applicable, have previously been delivered to UM: (i) all documents embodying or governing such Employee Plan (or for unwritten Employee Plans a written description of the material terms of such Employee Plan) and any funding
medium for the Employee Plan; (ii) the most recent IRS determination or opinion letter; (iii) the most recently filed Form 5500; (iv) the most recent actuarial valuation report; (v) the most recent summary plan description (or other
descriptions provided to employees) and all modifications thereto; (vi) the last three years of non-discrimination testing results; and (vii) all non-routine
correspondence to and from any governmental agency. 

  

	13.13	 Each Employee Plan is and has been established, operated, and administered in all material respects in
accordance with applicable laws and regulations and with its terms. 

  

	13.14	 Neither the execution and delivery of this Agreement, the shareholder approval of this Agreement, nor the
consummation of the transactions contemplated hereby could (either alone or in conjunction with any other event) (i) result in, or cause the accelerated vesting payment, funding or delivery of, or increase the amount or value of, any payment or
benefit to any employee, officer, director or other service provider of the Company or any of its ERISA Affiliates; (ii) further restrict any rights of the Company to amend or terminate any Employee Plan; (iii) result in any
“parachute payment” as defined in Section 280G(b)(2) of the Code (whether or not such payment is considered to be reasonable compensation for services rendered). 

 

	14.	 Statutory and legal requirements 

 

	14.1	 All statutory, municipal, governmental, court and other requirements applicable to the carrying on of the
business of the Company, the formation, continuance in existence, creation and issue of securities, management, property or operation of the Company have been complied with, and all permits, authorities, licences and consents have been obtained and
all conditions applicable thereto complied with and so far as the Warrantors are aware there are no circumstances which might lead to the suspension, alteration or cancellation of any such permits, authorities, licences or consents, nor is there any
agreement which materially restricts the fields within which the Company may carry on its business. Without limiting the foregoing: 

  

	 	(a)	 The Company possesses all permits, licenses, registrations, certificates, authorisations, orders and approvals
from the appropriate federal, state or foreign regulatory authorities necessary to conduct its business as now conducted, including all such permits, licenses, registrations, certificates, authorizations, orders and approvals required by any
agencies or bodies engaged in the regulation of drugs, pharmaceuticals, medical devices or biohazardous materials. The Company has not received any notice of proceedings relating to the suspension, modification, revocation or cancellation of any
such permit, license, registration, certificate, authorization, order or approval. Neither the Company nor, to the Company’s knowledge, any officer, employee or agent of the Company has been convicted of any crime or engaged in any

  
 33 

	 	
conduct that has previously caused or would reasonably be expected to result in (i) disqualification or debarment by the FDA under 21 U.S.C. Sections 335(a) or (b), or any similar law, rule
or regulation of any other governmental entities, (ii) debarment, suspension, or exclusion under any federal healthcare programs or by the General Services Administration, or (iii) exclusion under 42 U.S.C.
Section 1320a-7 or any similar law, rule or regulation of any governmental entities. Neither the Company nor any of its officers, employees, or, to the Company’s knowledge, any of its contractors or
agents is the subject of any pending or threatened investigation by FDA pursuant to the FDA Application Integrity Policy and any amendments thereto, or by any other similar governmental entity pursuant to any similar policy. Neither the Company nor
any of its officers, employees, contractors, and agents has committed any act, made any statement or failed to make any statement that would reasonably be expected to provide a basis for FDA to invoke the FDA Application Integrity Policy or for any
similar governmental entity to invoke a similar policy. Neither the Company nor any of its officers, employees, or to the Company’s knowledge, any of its contractors or agents has made any materially false statements on, or material omissions
from, any notifications, applications, approvals, reports and other submissions to FDA or any similar governmental entity; 

  

	 	(b)	 The Company is and has been in compliance with all applicable laws administered or issued by the FDA or any
similar governmental entity, including the Federal Food, Drug, and Cosmetic Act and all other laws regarding developing, testing, manufacturing, marketing, distributing or promoting the products of the Company, or complaint handling or adverse event
reporting; and 

  

	 	(c)	 Neither the Company nor any of its directors, officers, employees or agents have, directly or indirectly, made,
offered, promised or authorized any payment or gift of any money or anything of value to or for the benefit of any “foreign official” (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the
“FCPA”)), foreign political party or official thereof or candidate for foreign political office for the purpose of (i) influencing any official act or decision of such official, party or candidate, (ii) inducing such
official, party or candidate to use his, her or its influence to affect any act or decision of a foreign governmental authority, or (iii) securing any improper advantage, in the case of (i), (ii) and (iii) above in order to assist the
Company or any of its affiliates in obtaining or retaining business for or with, or directing business to, any person. Neither the Company nor any of its directors, officers, employees or agents have made or authorized any bribe, rebate, payoff,
influence payment, kickback or other unlawful payment of funds or received or retained any funds in violation of any law, rule or regulation. Neither the Company nor any of its officers, directors or employees are the subject of any allegation,
voluntary disclosure, investigation, prosecution or other enforcement action related to the FCPA or any other anti-corruption law. 

  

	14.2	 The Company has obtained all export licences required for all products, technology or services exported by or
on behalf of the Company to or from any part of the world. 

  

	14.3	 The Company does not engage in (a) the design, fabrication, development, testing, production or
manufacture of one (1) or more “critical technologies” within the meaning of the DPA, as amended, including all implementing regulations thereof; (b) the ownership, operation, maintenance, supply, manufacture, or servicing of
“covered investment critical infrastructure” within the meaning of the DPA (where such activities are covered by column 2 of Appendix A to 31 C.F.R. Part 800); or (c) the maintenance or collection, directly or indirectly, of
“sensitive personal data” of U.S. citizens within the meaning of the DPA. The Company has no current intention of engaging in such activities in the future. 

 

	14.4	 The Company has not committed and is not liable for any criminal, illegal, unlawful, ultra vires or
unauthorised act or breach of covenant, contract or statutory duty. 

  
 34 

	14.5	 No Key Person has: 

  

	 	(a)	 been convicted of a criminal offence (except any road traffic offence not punished by a custodial sentence);

  

	 	(b)	 been disqualified from being a company director; or 

 

	 	(c)	 given, or offered to give, a disqualification undertaking under section 1A of the Company Directors
Disqualification Act 1986. 

  

	14.6	 No person, not being a director of the Company, has any actual or ostensible authority, whether under a power
of attorney, agency agreement or otherwise, to commit the Company to any obligation other than an obligation of a nature which it is usual for it to incur in the ordinary course of its business. 

 

	14.7	 In respect of any Personal Data processed by the Company, the Company: 

 

	 	(a)	 has made all necessary registrations and notifications of its particulars in accordance with the Data
Protection Legislation or any similar applicable law in jurisdictions other than the United Kingdom in which the Company operates; 

  

	 	(b)	 has complied with the Data Protection Legislation (including but not limited to the Data Protection Principles)
and any guidance notes or guidelines issued from time to time by the Information Commissioner (and any successor) and all other relevant authorities, or any similar applicable law in jurisdictions other than the United Kingdom for which the Company
operates; 

  

	 	(c)	 has not received any enforcement notice, information notice, special information notice, monetary penalty
notice or other notice, letter or complaint alleging a breach by it of any of the provisions of the Data Protection Legislation or any similar applicable law in jurisdictions other than the United Kingdom for which the Company operates or requesting
information as to its data protection policies or practices and no circumstances exist which may give rise to any of the above; 

  

	 	(d)	 has not awarded compensation to an individual under the Data Protection Legislation, or any similar applicable
law in jurisdictions other than the United Kingdom for which the Company operates no claim for such compensation is outstanding and so far as the Warrantors are aware there is no reason to believe that any circumstances exist which might lead to any
claim for compensation being made; 

  

	 	(e)	 is not the subject of any order made against it for the rectification, blocking, erasure or destruction of any
data under the Data Protection Legislation or any similar applicable law in jurisdictions other than the United Kingdom for which the Company operates, no application for such an order is outstanding and, so far as the Warrantors are aware there is
no reason to believe that any circumstances exist which might lead to any application for such an order being made; and 

  

	 	(f)	 has not received any warrant issued under the Data Protection Legislation authorising the Information
Commissioner or other relevant authorities to enter any premises of the Company. 

  

	14.8	 In respect of any Grant Funding provided to the Company full details of which are set out in the Disclosure
Letter: 

  

	 	(a)	 The Company has complied in all respects with the terms and conditions on which any Grant Funding has been
provided to the Company. 

  

	 	(b)	 The entry into this Agreement and the fulfilment of the Business Plan will not: 

 

	 	(i)	 breach any terms or conditions of any Grant Funding; and 

 

	 	(ii)	 alter or abrogate any rights of the Company under any Grant Funding. 

  
 35 

	 	(c)	 No Grant Funding will be terminated or be required to be repaid as a result of the entry into this Agreement or
the fulfilment of the Business Plan. 

  

	14.9	 The studies, tests, preclinical development and clinical trials, if any, conducted by or on behalf of the
Company are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional and scientific standards for products or product candidates comparable to those being developed
by the Company and all applicable laws and regulations. The descriptions of, protocols for, and data and other results of, the studies, tests, development and trials conducted by or on behalf of the Company that have been furnished or made available
to UM are accurate and complete. The Warrantors are not aware of any studies, tests, development or trials the results of which reasonably call into question the results of the studies, tests, development and trials conducted by or on behalf of the
Company, and the Company has not received any notices or correspondence from any relevant governmental entity or any institutional review board or comparable authority requiring the termination, suspension or material modification of any studies,
tests, preclinical development or clinical trials conducted by or on behalf of the Company. 

  

	15.	 Records and registers 

 

	15.1	 The records (including computer records), statutory books, registers, minute books and books of account of the
Company are duly entered up and maintained in accordance with all legal requirements applicable thereto and contain true, full and accurate records of all matters required to be dealt with therein and all such books and all records and documents
(including documents of title) which are its property are in its possession or under its control. 

  

	15.2	 All accounts, documents and returns required to be delivered or made to the Registrar of Companies have been
duly and correctly delivered or made. There has been no notice of any proceedings to rectify the register of members of the Company or the Company’s persons with significant control (“PSC”) register and there are no
circumstances which might lead to any application for rectification of the register of members or the PSC register. 

  

	16.	 Insurance 

  

	16.1	 The Disclosure Letter contains a summary of all insurance policies held by the Company. In respect of such
insurances: 

  

	 	(a)	 all premiums have been duly paid to date; 

 

	 	(b)	 all the policies are in full force and effect and are not voidable on account of any act, omission or non-disclosure on the part of the insured party nor could they be declared null and void or as a consequence of which any claim might be rejected; and 

 

	 	(c)	 there are no circumstances which would or might give rise to any claim and no insurance claim is outstanding.

  

	16.2	 The Company has all insurance policies that would be reasonable and customary for companies like the Company,
with extended coverage, sufficient in amount (subject to reasonable deductions) to allow it to replace any of its properties that might be damaged or destroyed. 

 

	17.	 Group structure 

 

	17.1	 The Company does not have any Subsidiary nor has it at any time a member of or the beneficial owner of any
shares, securities or other interest in any company or other person. 

  

	18.	 Agreements and capital commitments 

 

	18.1	 The Company: 

  

	 	(a)	 has no material capital commitments; 

  
 36 

	 	(b)	 is not a party to any contract, arrangement or commitment (whether in respect of capital expenditure or
otherwise) which is of an unusual, onerous or long-term nature or which involves or could involve a material obligation or liability, including any contract, arrangement or commitment that includes milestone-based payments or royalties;

  

	 	(c)	 has not become bound and no person has become entitled (or with the giving of notice and/or the issue of a
certificate and/or the passage of time or otherwise may become entitled) to require it to repay any loan capital or other debenture, redeemable preference share capital, borrowed money or grant made to it by any governmental or other authority or
person prior to the stipulated due date; 

  

	 	(d)	 is not a party to any agreement which is or may become terminable as a result of the entry into or completion
of this Agreement; 

  

	 	(e)	 is not bound by any guarantee or contract of indemnity or suretyship under which any liability or contingent
liability is outstanding; 

  

	 	(f)	 has not entered into any agreement which requires or may require, or confers any right to require, the sale
(whether for cash or otherwise) or the transfer by it of any asset; 

  

	 	(g)	 is not a party to any joint venture, consortium, partnership, unincorporated association or profit sharing
arrangement or agreement; 

  

	 	(h)	 is not a party to or enjoys the benefit of any agreement requiring registration or notification under or by
virtue of any statute; 

  

	 	(i)	 is not a party to any contract that contains any non-competition or
similar obligations binding the Company or that otherwise prohibits the Company from entering into any line of business; 

  

	 	(j)	 is not a party to any contract in which the Company has granted exclusive marketing or distribution rights
relating to any products or territory; 

  

	 	(k)	 is not a party to any contract with any governmental authority or any academic institution;

  

	 	(l)	 is not a party to any manufacturing agreement; or 

 

	 	(m)	 is not in default of any agreement or arrangement to which it is a party which would enable the other party to
such agreement or arrangement to terminate or would give rise to material liability for the Company. 

  

	18.2	 The Company has not been and is not a party to any contract or arrangements binding upon it for the purchase or
sale of property or the supply of goods or services at a price different to that reasonably obtainable on an arm’s length basis. 

  

	19.	 Borrowings and facilities 

Full details of all limits on the Company’s bank overdraft facilities and all borrowings of the Company are set out in the Disclosure
Letter and the Company is not in breach of any of their terms and none of such facilities or terms of borrowing will be terminated as a result of the entry into of this Agreement. 

 

	20.	 Social obligations 

 

	20.1	 So far as the Warrantors are aware, the Company has during the three years ending on the date of this Agreement
complied with all its Social Obligations and it continues to do so. 

  
 37 

	20.2	 No person has in the last 12 months notified the Company of any alleged breach of its Social Obligations.

  

	21.	 Brokers’ and finders’ fees 

 

	21.1	 Neither the Company nor any of the Sellers have incurred, nor will incur, directly or indirectly, any liability
for brokerage or finders’ fees or agents’ commissions, fees related to investment banking or similar advisory services or any similar charges in connection with this Agreement or the transactions contemplated hereby, nor will UM or its
Subsidiaries (prior to or following Completion) incur, directly or indirectly, any such liability based on arrangements made by or on behalf of the Company or any of the Sellers. 

  
 38 

 SCHEDULE 4 : UM CAPITALISATION TABLE 

  
 39 

	
	[####]
	 [####]

	[####]
	[####]
	[####]
	[####]
	[####]
	[####]
	[####]
	[####]
	[####]
	[####]
	 [####]

	[####]
	[####]
	[####]
	[####]
	[####]
	[####]
	[####]
	[####]
	[####]
	[####]
	[####]
	[####]
	[####]
	[####]
	[####]
	[####]
	[####]
	[####]
	[####]
	[####]
	[####]
	 [####]

	[####]
	[####]

  
 40 

 SCHEDULE 5 : PARTICULARS OF THE COMPANY 

 

			
	Country of Incorporation:	  	England & Wales
		
	Registered number:	  	09088717
		
	Registered office:	  	C/O Medicxi, 25 Great Pulteney Street, London, England, W1F 9LT
		
	Directors:	  	Saurabh Saha
		
		  	Iqbal Hussain
		
		  	Marella Thorell
		
	Secretary:	  	The Cambridge Partnership Limited
		
	Accounting reference date:	  	30 December
		
	Charges:	  	None
		
	Auditors:	  	HBB Audit Limited
		
	Issued share capital:	  	£428.5574, consisting of 4,285,574 ordinary shares of £0.0001
		
	Shareholder:	  	UM

  
 41 

 This Agreement has been entered into on the date inserted on the first page of this Agreement: 

 

					
	                                    Richard Lee	  		  	
	Executed
by                                        
             	  	)	  	
	for and on behalf of	  	)	  	
	UNITED MEDICINES BIOPHARMA LIMITED	  	)	  	 /s/ Richard Lee

		  		  	Signature
			
	[####]	  		  	
	Executed
by                                       
              	  	)	  	[####]
	for and on behalf of	  	)	  	[####]
	 APCINTEX LIMITED
	  	)	  	 [####]

		  		  	Signature
			
	Executed
by                                       
              	  	)	  	
	for and on behalf of	  	 	  	
	 [####]
 [####]

[####]
	  	  
  

)
	  	 [####]
 [####]

[####]

		  		  	Signature                    Director
		  		  	
			
	Executed
by                                       
              	  	)	  	
	for and on behalf of	  	)	  	
	 [####]
 [####]

[####]
 [####]
	  	  
 )
	  	 [####]
 [####]

[####]

		  		  	  

Signature                  Director

			
	Executed by [####]	  	)	  	
	for and on behalf of	  	)	  	
	 [####]
 [####]

[####]
	  	 )
	  	 [####]
 [####]

[####]

		  		  	  
 Signature

			
	Executed by [####]	  	)	  	
	for and on behalf of	  	)	  	 [####]
 [####] 

[####]

	[####]	  	 
	[####]	  	)
		  		  	  
 Signature

  
 42 

					
	Executed by	  	)	  	
	for and on behalf of	  		  	                [####]
	[####]	  	)	  	                [####]
		  	)	  	  

		  		  	Signature
			
	Executed by	  	)	  	                 [####]

                [####]

                [####]

	for and on behalf of	  	)
	[####]	  	)
		  		  	Signature
			
	Executed by	  	)	  	                [####]
	[####]	  	)	  	                [####]
		  	)	  	
                [####]

		  		  	Signature
			
	Executed by	  	)	  	                [####]
	[####]	  	)	  	                [####]
		  	)	  	
                [####]

		  		  	Signature
			
	Executed by	  	)	  	                [####]
	[####]	  	)	  	                [####]
		  	)	  	
                [####]

		  		  	Signature
			
	Executed by	  	)	  	                [####]
	[####]	  	)	  	                [####]
		  	)	  	
                [####]

		  		  	Signature
			
	Executed by	  	)	  	                [####]
	[####]	  	)	  	                [####]
		  	)	  	
                [####]

		  		  	Signature
			
	Executed by	  	)	  	                [####]
	[####]	  	)	  	                [####]
		  	)	  	
                [####]

		  		  	Signature
			
	Executed by	  	)	  	                [####]
	[####]	  	)	  	                [####]
		  	)	  	
                [####]

		  		  	Signature

  
 43

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]